Rhythm Control versus Rate Control for Atrial Fibrillati

New England Journal of Medicine 358, 2667-2677 DOI: 10.1056/nejmoa0708789

Citation Report

#	Article	IF	CITATIONS
1	Reviews : VON KNUD KRAKAU. Die Harmon Doktrin : Eine These der Vereinigten Staaten zum internationalen Flubrecht. Hamburg, Institut für Auswätige Politik, 1966. Pp. 139. Price not indicated. International Studies, 1967, 9, 372-373.	0.5	0
3	Computational approaches to structural and functional analysis of plastocyanin and other blue copper proteins. Cellular and Molecular Life Sciences, 2004, 61, 1123-1142.	2.4	24
4	Biochemistry and biology of mammalian DNA methyltransferases. Cellular and Molecular Life Sciences, 2004, 61, 2571-2587.	2.4	462
5	Acute effects of adrenergic agents on post-defibrillation arrest time in a cultured heart model. Cellular and Molecular Life Sciences, 2004, 61, 3093-3099.	2.4	3
6	Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons. Cellular and Molecular Life Sciences, 2005, 62, 227-238.	2.4	23
7	New Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation. Herz, 2008, 33, 562-567.	0.4	6
9	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.	1.0	2,656
10	Stroke risk might be specifically correlated with the burden of paroxysmal atrial fibrillation. Journal of Internal Medicine, 2008, 264, 401-401.	2.7	0
11	Atrial Fibrillation (AF) and Heart Failure (HF): To Treat the AF, be Sure to Treat the HF. Progress in Cardiovascular Nursing, 2008, 23, 146-149.	0.5	3
12	The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology, 2008, 51, 2075-2081.	1.2	4
13	The Year in Heart Failure. Journal of the American College of Cardiology, 2008, 52, 1671-1678.	1.2	5
15	Pathophysiology of atrial fibrillation: Insights into the renin–angiotensin system. Archives of Cardiovascular Diseases, 2008, 101, 787-791.	0.7	5
16	Treatment of atrial fibrillation. British Medical Bulletin, 2008, 88, 75-94.	2.7	38
17	GuÃa de práctica clÃnica de la Sociedad Europea de CardiologÃa (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008). Revista Espanola De Cardiologia, 2008, 61, 1329.e1-1329.e70.	0.6	36
18	Optimizing the treatment of atrial fibrillation: contributions by remote monitoring. Europace, 2008, 11, 7-8.	0.7	5
19	Rhythm Control in Atrial Fibrillation — One Setback after Another. New England Journal of Medicine, 2008, 358, 2725-2727.	13.9	23
20	Vernakalant (RSD1235) in the management of atrial fibrillation: a review of pharmacological properties, clinical efficacy and safety. Future Cardiology, 2008, 4, 559-567.	0.5	2
21	Rhythm Control versus Rate Control for Atrial Fibrillation. New England Journal of Medicine, 2008, 359, 1522-1522.	13.9	7

#	Article	IF	CITATIONS
23	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008‡. European Journal of Heart Failure, 2008, 10, 933-989.	2.9	1,893
25	Treatment of Atrial Fibrillation and Atrial Flutter. Cardiology in Review, 2008, 16, 230-239.	0.6	12
26	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 676-682.	0.4	0
27	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 1024-1029.	0.4	1
28	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2008, 43, 770-774.	0.4	0
30	Atrial Fibrillation and Other Rhythm Disturbances in the Elderly. , 0, , 139-150.		0
31	Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options. Journal of Managed Care Pharmacy, 2009, 15, 10-18.	2.2	26
32	Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation. Expert Review of Cardiovascular Therapy, 2009, 7, 311-322.	0.6	5
33	Pharmacological and Electrical Conversion of Atrial Fibrillation to Sinus Rhythm Is Worth the Effort. Circulation, 2009, 120, 1436-1443.	1.6	29
34	Upstream therapy of atrial fibrillation. Expert Review of Cardiovascular Therapy, 2009, 7, 763-778.	0.6	24
35	Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opinion on Emerging Drugs, 2009, 14, 233-249.	1.0	35
36	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation, 2009, 119, e391-479.	1.6	2,001
37	Atrial fibrillation: cure or treat?. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 187-196.	1.0	8
38	I _{Kur} /Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opinion on Investigational Drugs, 2009, 18, 399-416.	1.9	69
39	Is It Time to Treat Depression in Patients With Cardiovascular Disease?. Circulation, 2009, 120, 99-100.	1.6	46
40	Relationship of Paroxysmal Atrial Tachyarrhythmias to Volume Overload. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 488-494.	2.1	32
41	Atrial Fibrillation and Acute Decompensated Heart Failure. Circulation: Heart Failure, 2009, 2, 72-73.	1.6	32
42	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation, 2009, 119, 1977-2016.	1.6	1,423

		CITATION REPORT	
#	Article	IF	CITATIONS
43	New Therapies for Stroke Prevention in Atrial Fibrillation. Circulation, 2009, 120, 1024-1026.	1.6	7
44	A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. European Heart Journal, 2009, 30, 2029-2037.	1.0	70
45	Primary prevention of atrial fibrillation by statins: still unresolved?. European Heart Journal, 2009, 3 2302-2303.	0, 1.0	3
46	Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations. European Heart Journal, 2009, 30, 2438-2440.	1.0	4
47	Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Europace, 2009, 11, 886-891.	0.7	35
48	The risk of antiarrhythmic drugs in atrial fibrillation: 20 years of controversies. Europace, 2009, 11, 840-841.	0.7	4
49	Undetected paroxysmal atrial fibrillation in chronic heart failure patients: is it clinically relevant to catch the atrial phantom?. Europace, 2009, 11, 1257-1259.	0.7	3
50	Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Review of Cardiovascular Therapy, 2009, 7, 473-481.	0.6	8
52	Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace, 2009, 11, 860-885.	0.7	104
53	Atrial fibrillation and congestive heart failure: should we aim to control the heart's rate or its rhythm?. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 6-7.	3.3	1
54	Pharmacological therapy for atrial fibrillation: current options and new agents. Expert Opinion on Investigational Drugs, 2009, 18, 417-431.	1.9	5
55	Dronedarone. Circulation, 2009, 120, 636-644.	1.6	142
56	Kv1.5 Blockers for the Treatment of Atrial Fibrillation: Approaches to Optimization of Potency and Selectivity and Translation to In Vivo Pharmacology. Current Topics in Medicinal Chemistry, 2009, 9 436-451.), 1.0	24
58	A metaâ€analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Europea Journal of Heart Failure, 2009, 11, 676-683.	n 2.9	312
59	Modification of cardiovascular ion channels by gene therapy. Expert Review of Cardiovascular Therapy, 2009, 7, 939-953.	0.6	5
60	Congestive heart failure with and without atrial fibrillation – different patient populations?. Scandinavian Cardiovascular Journal, 2009, 43, 169-175.	0.4	4
61	Prevention of Atrial Fibrillation. Circulation, 2009, 119, 606-618.	1.6	446
62	Managing Patients with Rapid Atrial Fibrillation and Decompensated Heart Failure. Circulation: Hear Failure, 2009, 2, 71-71.	rt 1.6	2

	Сітатіо	n Report	
#	Article	IF	CITATIONS
63	Atrial Fibrillation and Heart Failure. Circulation, 2009, 119, 2516-2525.	1.6	530
64	Elevated Depression Symptoms Predict Long-Term Cardiovascular Mortality in Patients With Atrial Fibrillation and Heart Failure. Circulation, 2009, 120, 134-140.	1.6	212
65	Cardioversion of Atrial Fibrillation for Maintenance of Sinus Rhythm: A Road to Nowhere. Circulation, 2009, 120, 1444-1452.	1.6	20
66	Can the NICE guidelines on the management of atrial fibrillation improve its management?. Clinical Medicine, 2009, 9, 207-209.	0.8	0
67	Can we improve outcomes in AF patients by early therapy?. BMC Medicine, 2009, 7, 72.	2.3	20
70	Comparison of Beta Blocker and Digoxin Alone and in Combination for Management of Patients With Atrial Fibrillation and Heart Failure. American Journal of Cardiology, 2009, 103, 248-254.	0.7	67
72	Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD. American Journal of Kidney Diseases, 2009, 53, 701-710.	2.1	18
75	Current atrial fibrillation guidelines and therapy algorithms: Are they adequate?. Journal of Interventional Cardiac Electrophysiology, 2009, 25, 111-116.	0.6	3
76	Clinical Trials Update from the European Society of Cardiology Congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE. Cardiovascular Drugs and Therapy, 2009, 23, 25-29.	1.3	1
77	New and emerging antiarrhythmic drugs for atrial fibrillation: What may become available to the clinician in the near future. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 373-380.	0.4	6
78	Tachycardia-mediated cardiomyopathy: Recognition and management. Current Heart Failure Reports, 2009, 6, 257-264.	1.3	37
79	Atrial Fibrillation Significantly Increases Total Mortality and Stroke Risk Beyond that Conveyed by the CHADS2 Risk Factors. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 981-986.	0.5	72
80	Cardioversion for Atrial Fibrillation: Treatment Options and Advances. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1073-1084.	0.5	22
81	Ranolazine Exerts Potent Effects on Atrial Electrical Properties and Abbreviates Atrial Fibrillation Duration in the Intact Porcine Heart. Journal of Cardiovascular Electrophysiology, 2009, 20, 796-802.	0.8	100
82	New Pharmacological Strategies for the Treatment of Atrial Fibrillation. Annals of Noninvasive Electrocardiology, 2009, 14, 290-300.	0.5	22
83	Atrial fibrillation and the risk of death in patients with heart failure: a literatureâ€based metaâ€analysis. Internal Medicine Journal, 2010, 40, 347-356.	0.5	35
84	FLECAINIDE TOXICITY IN AN OLDER ADULT. Journal of the American Geriatrics Society, 2009, 57, 751-753.	1.3	5
85	Pulmonary vein isolation of symptomatic refractory paroxysmal and persistent atrial fibrillation. Netherlands Heart Journal, 2009, 17, 366-372.	0.3	7

#	Article	IF	CITATIONS
86	Is there a heart rate paradox – demystification of the myths?. Journal of Internal Medicine, 2009, 266, 242-247.	2.7	4
87	Dronedarone: a new option in atrial fibrillation. Future Prescriber, 2009, 10, 24-32.	0.1	1
89	The normalization heuristic: An untested hypothesis that may misguide medical decisions. Medical Hypotheses, 2009, 72, 745-748.	0.8	13
90	Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials. American Heart Journal, 2009, 158, 15-20.	1.2	24
91	Does intensity of rate control influence outcome in persistent atrial fibrillation?. American Heart Journal, 2009, 158, 785-791.	1.2	29
92	2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 2009, 53, 1343-1382.	1.2	212
93	The Utility of 12-Lead Holter Monitoring in Patients With Permanent Atrial Fibrillation for the Identification of Nonresponders After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2009, 53, 1050-1055.	1.2	163
94	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2009, 54, 1280-1289.	1.2	129
95	The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology, 2009, 54, 777-787.	1.2	1
96	Appropriate Evaluation and Treatment of Heart Failure Patients After Implantable Cardioverter-Defibrillator Discharge. Journal of the American College of Cardiology, 2009, 54, 1993-2000.	1.2	60
97	Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil. Expert Opinion on Investigational Drugs, 2009, 18, 1191-1196.	1.9	3
98	New Pharmacological Options for Patients With Atrial Fibrillation: The ATHENA Trial. Revista Espanola De Cardiologia (English Ed), 2009, 62, 479-481.	0.4	2
99	Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management. Nature Clinical Practice Cardiovascular Medicine, 2009, 6, 46-56.	3.3	39
100	Non-investigational antiarrhythmic drugs: long-term use and limitations. Expert Opinion on Drug Safety, 2009, 8, 345-355.	1.0	3
101	Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure. Expert Review of Cardiovascular Therapy, 2009, 7, 779-787.	0.6	5
102	A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study). Heart, 2009, 95, 924-930.	1.2	159
103	Heart failure. Lancet, The, 2009, 373, 941-955.	6.3	152
104	Delirium cordis: can we predict the onset of atrial fibrillation?. Lancet, The, 2009, 373, 698-700.	6.3	6

#	ARTICLE 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and	IF	CITATIONS
107	Management of Heart Failure in Adults. Journal of the American College of Cardiology, 2009, 53, e1-e90.	1.2	1,386
108	Rate control during atrial fibrillation achieved by chronic endocardial vagal stimulation: Proof of principle. Heart Rhythm, 2009, 6, 1287-1288.	0.3	1
109	Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clinic Proceedings, 2009, 84, 234-242.	1.4	62
110	Women with atrial fibrillation: Greater risk, less attention. Gender Medicine, 2009, 6, 419-432.	1.4	69
111	Milestones in the management of atrial fibrillation. Heart Rhythm, 2009, 6, S62-S67.	0.3	34
112	Drug Therapy for Atrial Fibrillation. Cardiology Clinics, 2009, 27, 109-123.	0.9	7
113	Atrial Fibrillation in Congestive Heart Failure: Current Management. Cardiology Clinics, 2009, 27, 79-93.	0.9	3
114	Les troubles du rythme supraventriculaires en réanimation. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2009, 18, 246-253.	0.1	0
115	Atrial Fibrillation: Goals of Therapy and Management Strategies to Achieve the Goals. Cardiology Clinics, 2009, 27, 189-200.	0.9	17
116	"Zooming in―to new horizons: Conduction abnormalities and other research perspectives in atrial fibrillation. Heart Rhythm, 2009, 6, 1118-1119.	0.3	0
117	Update on medical management of atrial fibrillation in the modern era. Heart Rhythm, 2009, 6, S17-S22.	0.3	9
118	Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Current Opinion in Cardiology, 2009, 24, 50-55.	0.8	44
119	Atrial fibrillation and congestive heart failure. Current Opinion in Cardiology, 2009, 24, 29-34.	0.8	33
120	Effectiveness of catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation. Current Opinion in Cardiology, 2009, 24, 9-17.	0.8	5
122	Learning From Clinical Randomized Trials. Circulation Journal, 2009, 73, 229-230.	0.7	0
123	Internal Medicine, 2009, 98, 2181-2187.	0.0	0
124	Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. Yearbook of Cardiology, 2009, 2009, 474-475.	0.0	1
125	Effects of Atrial Fibrillation on Long-Term Outcomes in Patients Hospitalized for Heart Failure in Japan A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circulation Journal, 2009, 73, 2084-2090.	0.7	71

#	Article	IF	CITATIONS
127	Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference â€~research perspectives in AF'. European Heart Journal, 2009, 30, 2969-2980.	1.0	173
128	Atrial fibrillation: still a benign condition in the elderly?. Aging Health, 2010, 6, 207-209.	0.3	0
129	Role of sotalol in rhythm control of atrial fibrillation. Therapy: Open Access in Clinical Medicine, 2010, 7, 391-407.	0.2	0
130	Dronedarone – A New Alternative for Management of Atrial Fibrillation. Recent Patents on Cardiovascular Drug Discovery, 2010, 5, 47-53.	1.5	2
131	A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFÉ-II Study). Yearbook of Cardiology, 2010, 2010, 521-523.	0.0	99
132	Atrial Fibrillation in Congestive Heart Failure. Cardiology in Review, 2010, 18, 38-50.	0.6	41
133	The 2010 Update of the ESC Guidelines for the Management of Atrial Fibrillation - What the Changes Will Mean for Clinicians Circulation Journal, 2010, 74, 2534-2537.	0.7	11
134	The 2010 Update of the ESC Guidelines for the Management of Atrial Fibrillation - Beyond the Rate or Rhythm Strategy Debate Circulation Journal, 2010, 74, 2538-2541.	0.7	2
135	Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. Canadian Journal of Emergency Medicine, 2010, 12, 181-191.	0.5	111
136	Atrial fibrillation in women. Therapy: Open Access in Clinical Medicine, 2010, 7, 139-146.	0.2	2
137	Is there a role for cardioversion in the management of atrial fibrillation?. Therapy: Open Access in Clinical Medicine, 2010, 7, 159-162.	0.2	1
139	Catheter Ablation Is Established as a Treatment Option for Atrial Fibrillation - Is Catheter Ablation Established as a Treatment Option of Atrial Fibrillation? (Pro) Circulation Journal, 2010, 74, 1972-1977.	0.7	15
140	Pharmacotherapeutic decision-making for patients with atrial fibrillation. American Journal of Health-System Pharmacy, 2010, 67, S17-S25.	0.5	5
141	Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program. Netherlands Heart Journal, 2010, 18, 471-477.	0.3	31
143	Sex Differences in Atrial Fibrillation and Its Complications. Current Cardiovascular Risk Reports, 2010, 4, 237-243.	0.8	1
144	Atrial fibrillation—rate or rhythm control?. Clinical Research in Cardiology Supplements, 2010, 5, 11-15.	2.0	1
145	New concepts in understanding antiarrhythmic effects. Clinical Research in Cardiology Supplements, 2010, 5, 42-46.	2.0	0
147	Avances en la prevención de la isquemia cerebral por fibrilación auricular. NeurologÃa, 2010, 25, 401-408.	0.3	13

#	Article	IF	CITATIONS
148	Drugâ€Induced QTâ€Interval Prolongation: Considerations for Clinicians. Pharmacotherapy, 2010, 30, 684-701.	1.2	63
149	Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers. Pharmacotherapy, 2010, 30, 867-871.	1.2	1
150	Dronedarone: A New Antiarrhythmic Agent. Pharmacotherapy, 2010, 30, 904-915.	1.2	27
151	Prognosis of Atrial Fibrillation in Patients with Symptomatic Peripheral Arterial Disease: Data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. European Journal of Vascular and Endovascular Surgery, 2010, 40, 9-16.	0.8	58
152	Thromboembolism in Atrial Fibrillation. American Journal of Cardiology, 2010, 105, 502-510.	0.7	128
153	Meta-Analysis of the Effectiveness and Safety of Catheter Ablation of Atrial Fibrillation in Patients With Versus Without Left Ventricular Systolic Dysfunction. American Journal of Cardiology, 2010, 106, 1284-1291.	0.7	104
155	Ablation vs Medical Therapy in the Setting of Symptomatic Atrial Fibrillation and Left Ventricular Dysfunction. Congestive Heart Failure, 2010, 16, 10-14.	2.0	47
159	Imminent Ganglionic Ventricular Rate Control During Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2010, 21, 200-202.	0.8	1
160	Is Rhythm ontrol Superior to Rate ontrol in Patients with Atrial Fibrillation and Diastolic Heart Failure?. Annals of Noninvasive Electrocardiology, 2010, 15, 209-217.	0.5	24
162	Dronedarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation. Core Evidence, 2010, 5, 49.	4.7	Ο
164	A Review of the Appropriate and Inappropriate Use of Dronedarone: Lessons Learned From Controlled Studies and Regulatory Submission. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 24S-30S.	1.0	7
165	Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 19S-23S.	1.0	5
166	Efficacy and safety of dronedarone: a review of randomized trials. Expert Opinion on Drug Safety, 2010, 9, 189-199.	1.0	17
167	<i>Circulation</i> Cardiovascular Case Series. Circulation, 2010, 122, 1661-1661.	1.6	Ο
168	Prevention of Stroke in Patients with Atrial Fibrillation: The Role of New Antiarrhythmic and Antithrombotic Drugs. Cerebrovascular Diseases, 2010, 30, 314-322.	0.8	8
169	Long-term outcome after catheter ablation for atrial fibrillation: safety, efficacy and impact on prognosis. Heart, 2010, 96, 1259-1263.	1.2	25
170	Heart Failure in Clinical Practice. , 2010, , .		8
171	Review: Optimizing the Management of Atrial Fibrillation: Focus on Current Guidelines and the Impact of New Agents on Future Recommendations. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 244-256.	1.0	2

#	Article	IF	CITATIONS
172	Prevention of cardioembolic stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2010, 8, 1405-1415.	0.6	6
174	Atrial fibrillation in heart failure is associated with an increased risk of death only in patients with ischaemic heart disease. European Journal of Heart Failure, 2010, 12, 692-697.	2.9	26
175	Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Heart, 2010, 96, 838-842.	1.2	31
176	Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. European Respiratory Review, 2010, 19, 72-82.	3.0	105
177	What an emergency physician needs to know about acute care of cardiac arrhythmias. Journal of Emergencies, Trauma and Shock, 2010, 3, 126.	0.3	3
178	Arzneiverordnungs-Report 2010. , 2010, , .		41
179	Early management of atrial fibrillation: from imaging to drugs to ablation. Nature Reviews Cardiology, 2010, 7, 345-354.	6.1	12
181	Comorbidities in Heart Failure. , 2010, , 257-270.		1
182	Atrial fibrillation and long-term prognosis in patients hospitalized for heart failure: results from heart failure survey in Israel (HFSIS). European Heart Journal, 2010, 31, 309-317.	1.0	34
183	Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome. European Heart Journal, 2010, 31, 983-983.	1.0	7
184	Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study. European Heart Journal, 2010, 31, 976-983.	1.0	77
185	Drugs vs. ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablation. European Heart Journal, 2010, 31, 1046-1054.	1.0	95
186	Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace, 2010, 12, 24-29.	0.7	73
187	Atrial fibrillation ablation in systolic heart failure patients: a promising tool?. Europace, 2010, 12, 1-2.	0.7	3
188	Advances in Prevention and Health Services Delivery 2009. Stroke, 2010, 41, e71-3.	1.0	4
189	Interventional management of atrial fibrillation. Expert Review of Cardiovascular Therapy, 2010, 8, 949-958.	0.6	2
191	Pulmonary vein isolation for the treatment of atrial fibrillation: past, present and future. Future Cardiology, 2010, 6, 51-66.	0.5	4
192	New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology, 2010, 7, 139-148.	6.1	61

#	Article	IF	CITATIONS
196	Cardiac arrhythmias in congestive heart failure. Expert Review of Cardiovascular Therapy, 2010, 8, 137-140.	0.6	4
197	Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy, 2010, 8, 695-715.	0.6	22
198	Clinical Pearls in Cardiology. Mayo Clinic Proceedings, 2010, 85, 473-478.	1.4	2
199	Atrial Fibrillation in Congestive Heart Failure. Heart Failure Clinics, 2010, 6, 187-200.	1.0	112
200	Rate Control in Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2010, 2, 419-427.	0.7	0
201	Ion channel trafficking: A new therapeutic horizon for atrial fibrillation. Heart Rhythm, 2010, 7, 1309-1315.	0.3	20
202	Pharmacologic Conversion of Atrial Fibrillation and Atrial Flutter. Cardiac Electrophysiology Clinics, 2010, 2, 393-407.	0.7	2
203	Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney International, 2010, 77, 1098-1106.	2.6	357
204	Atrial Fibrillation Ablation. , 2010, , 235-261.		0
205	Guidelines for Atrial Fibrillation in Heart Failure Need To Be Clarified. Journal of the American College of Cardiology, 2010, 55, 167.	1.2	1
206	The Year in Heart Failure. Journal of the American College of Cardiology, 2010, 55, 688-696.	1.2	14
207	Maintenance of Sinus Rhythm and Survival in Patients With Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2010, 55, 1796-1802.	1.2	129
208	¿Qué estrategia seguir y en qué pacientes?. Cardiocore, 2010, 45, 96-99.	0.0	1
209	Réduire ou ralentir la fibrillation auriculaire : est-ce la bonne question en 2010 ?. Archives of Cardiovascular Diseases Supplements, 2010, 2, 188-195.	0.0	0
212	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	1.0	4,635
213	Should all patients with non-valvular atrial fibrillation be anticoagulated?. International Journal of Cardiology, 2010, 143, 8-15.	0.8	7
216	New pharmacological targets and treatments for atrial fibrillation. Trends in Pharmacological Sciences, 2010, 31, 364-371.	4.0	10
217	Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial. American Heart Journal, 2010, 159, 857-863.	1.2	22

#	Article	IF	CITATIONS
218	Atrial Fibrillation in Heart Failure: A Comprehensive Review. American Journal of Medicine, 2010, 123, 198-204.	0.6	94
219	Dronedarone: Current Evidence and Future Questions. Cardiovascular Therapeutics, 2010, 28, 38-47.	1.1	12
220	REVIEW: New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. Cardiovascular Therapeutics, 2010, 28, 302-310.	1.1	21
221	Chronic Cardiac Failure. , 2010, , 272-285.		1
222	Chronic Heart Failure: Contemporary Diagnosis and Management. Mayo Clinic Proceedings, 2010, 85, 180-195.	1.4	177
225	New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet, The, 2010, 375, 1212-1223.	6.3	261
227	Sinus rhythm is associated with fewer heart failure symptoms: Insights from the AFFIRM trial. Heart Rhythm, 2010, 7, 596-601.	0.3	50
228	Rate versus rhythm control in atrial fibrillation: no one-size-fits-all. Expert Review of Cardiovascular Therapy, 2010, 8, 891-893.	0.6	0
229	Dronedarone: NICE enough?. Expert Review of Cardiovascular Therapy, 2010, 8, 1049-1051.	0.6	0
230	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	0.7	1,360
231	Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Current Medical Research and Opinion, 2011, 27, 995-1003.	0.9	13
232	Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart, 2011, 97, 740-747.	1.2	282
233	HRS Policy Statement: Clinical Cardiac Electrophysiology Fellowship Curriculum: Update 2011. Heart Rhythm, 2011, 8, 1340-1356.	0.3	13
234	Advances in the Pharmacologic Management of Atrial Fibrillation. Cardiac Electrophysiology Clinics, 2011, 3, 157-167.	0.7	0
236	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq	0 0 0 rgB1 1.2	- /Qyerlock 10 262
237	Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 493-501.	1.2	159
238	Lenient Versus Strict Rate Control in Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 950-952.	1.2	12
239	Rhythm Control for Atrial Fibrillation. Journal of the American College of Cardiology, 2011, 58, 1986-1988.	1.2	1

#	Article	IF	CITATIONS
241	Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial. Trials, 2011, 12, 44.	0.7	6
242	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0
243	Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace, 2011, 13, 308-328.	0.7	249
244	Mitral Valve Surgery. , 2011, , .		2

2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq0 8.9 rgBT /Overlock 10

CITATION REPORT

246	Management of Atrial Fibrillation: Translating Clinical Trial Data into Clinical Practice. American Journal of Medicine, 2011, 124, 4-14.	0.6	17
247	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Canadian Journal of Cardiology, 2011, 27, 47-59.	0.8	112
248	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Implementing GRADE and Achieving Consensus. Canadian Journal of Cardiology, 2011, 27, 27-30.	0.8	29
249	Comparing the 2010 North American and European Atrial Fibrillation Guidelines. Canadian Journal of Cardiology, 2011, 27, 7-13.	0.8	28
250	Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Management of Recent-Onset Atrial Fibrillation and Flutter in the Emergency Department. Canadian Journal of Cardiology, 2011, 27, 38-46.	0.8	117
251	New and Emerging Drugs and Device Therapies for Chronic Heart Failure in Patients With Systolic Ventricular Dysfunction. Canadian Journal of Cardiology, 2011, 27, 296-301.	0.8	15
252	Atrial Fibrillation: A Real-Life Observational Study in the Québec Population. Canadian Journal of Cardiology, 2011, 27, 794-799.	0.8	5
253	"Show Me the Moneyâ€! The Cost of Atrial Fibrillation. Canadian Journal of Cardiology, 2011, 27, 401-403.	0.8	0
254	Hospitalization Epidemic in Patients With Heart Failure: Risk Factors, Risk Prediction, Knowledge Gaps, and Future Directions. Journal of Cardiac Failure, 2011, 17, 54-75.	0.7	240
255	Catheter Ablation for Atrial Fibrillation in Patients With Left Ventricular Systolic Dysfunction. A Systematic Review and Meta-Analysis. Journal of Cardiac Failure, 2011, 17, 964-970.	0.7	123
256	Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials. European Journal of Internal Medicine, 2011, 22, 448-455.	1.0	34
257	Antiarrhythmic drugs for atrial fibrillation. Expert Opinion on Pharmacotherapy, 2011, 12, 1201-1215.	0.9	4
258	Atrial fibrillation: Pathophysiology and current therapy, Annals of Medicine, 2011, 43, 425-436.	1.5	3

#	Article	IF	Citations
259	A comparison between monophasic and biphasic defibrillation for the cardioversion of persistent atrial fibrillation in patients with and without heart failure. International Journal of Cardiology, 2011, 147, 405-408.	0.8	4
260	Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial) Tj ETQq1 1 0.7843	14 rgBT /(0.8	Overlock 10
261	Rate vs. rhythm control in patients with atrial fibrillation — An updated meta-analysis of 10 randomized controlled trials. International Journal of Cardiology, 2011, 153, 96-98.	0.8	14
262	Enfermedad cardiovascular en el anciano. Revista Espanola De Cardiologia, 2011, 64, 697-712.	0.6	59
263	Treating arrhythmias: an expert opinion. Expert Opinion on Pharmacotherapy, 2011, 12, 1359-1367.	0.9	7
264	Cardiovascular Disease in the Elderly. Revista Espanola De Cardiologia (English Ed), 2011, 64, 697-712.	0.4	13
265	2011 Update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of chronic heart failure in Australia, 2006. Medical Journal of Australia, 2011, 194, 405-409.	0.8	128
266	Stepwise Approach for Ablation of Persistent Atrial Fibrillation. , 2011, , 304-315.		0
267	PROSPECTS FOR THE TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2011, 7, 323-333.	0.3	5
268	Management of Arrhythmias in Heart Failure. , 2011, , 765-786.		1
269	Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions. Thrombosis and Haemostasis, 2011, 105, 1010-1023.	1.8	69
270	Pulmonary Vein Isolation for Atrial Fibrillation. , 2011, , 234-264.		2
271	Is dronedarone more effective than amiodarone?. JAAPA: Official Journal of the American Academy of Physician Assistants, 2011, 24, 56-58.	0.1	0
272	Current and emerging therapies for stroke prophylaxis in atrial fibrillation. Clinical Investigation, 2011, 1, 1019-1037.	0.0	0
275	Cost Effectiveness of Radiofrequency Catheter Ablation vs. Medical Treatment for Atrial Fibrillation in Japan - Cost Performance for Atrial Fibrillation Circulation Journal, 2011, 75, 1860-1866.	0.7	14
276	Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation - A Report From the J-RHYTHM Registry Circulation Journal, 2011, 75, 1328-1333.	0.7	188
277	Rhythm Control Should Be Better for the Management of Patients With Atrial Fibrillation and Heart Failure - Rhythm Control vs. Rate Control: Which Is Better in the Management of Atrial Fibrillation? (Rhythm-Side) Circulation Journal, 2011, 75, 979-985.	0.7	13
278	Rate Control Is a Better Initial Treatment for Patients With Atrial Fibrillation and Heart Failure - Rhythm Control vs. Rate Control: Which Is Better in the Management of Atrial Fibrillation? (Rate-Side) Circulation Journal, 2011, 75, 970-978.	0.7	7

#	Article	IF	CITATIONS
279	Clinical Outcome in Patients With Paroxysmal or Persistent Atrial Fibrillation Receiving Bepridil. Circulation Journal, 2011, 75, 1334-1342.	0.7	17
280	Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence. Clinical Investigation, 2011, 1, 579-588.	0.0	1
281	The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. Journal of Internal Medicine, 2011, 270, 281-290.	2.7	34
282	Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 247-259.	0.5	12
283	Patients Treated with Catheter Ablation for Atrial Fibrillation Have Longâ€Term Rates of Death, Stroke, and Dementia Similar to Patients Without Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2011, 22, 839-845.	0.8	349
284	Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure. Journal of Cardiology, 2011, 58, 108-115.	0.8	17
285	Novel pharmacological targets for the rhythm control management of atrial fibrillation. , 2011, 132, 300-313.		29
286	Comparison of Rate Control versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Costâ€Effectiveness Analysis. Pharmacotherapy, 2011, 31, 552-565.	1.2	16
287	Atrial Fibrillation: Pharmacological Therapy. Current Problems in Cardiology, 2011, 36, 87-120.	1.1	6
288	Assessing patients for catheter ablation during hospitalization for acute heart failure. Heart Failure Reviews, 2011, 16, 467-476.	1.7	11
289	Post-ATHENA and beyond. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 55-60.	0.6	2
290	Cryoablation of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2011, 32, 233-242.	0.6	13
291	Diagnostic accuracy of NT-proBNP ratio (BNP-R) for early diagnosis of tachycardia-mediated cardiomyopathy: a pilot study. Clinical Research in Cardiology, 2011, 100, 887-896.	1.5	32
292	Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clinical Research in Cardiology, 2011, 100, 897-905.	1.5	87
293	What is the role of the cardiologist in future management of stroke prevention in atrial fibrillation?. Advances in Therapy, 2011, 28, 1-12.	1.3	5
294	Effect of catheter ablation on the left ventricular mass index and other echocardiograph parameters in atrial fibrillation patients: comparison with antiarrhythmic drug treatment. Journal of Echocardiography, 2011, 9, 51-58.	0.4	4
295	Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes. Journal of General Internal Medicine, 2011, 26, 531-537.	1.3	14
296	Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study. BMC Cardiovascular Disorders, 2011, 11, 19.	0.7	9

#	Article	IF	CITATIONS
297	Managing Recent-Onset Atrial Fibrillation in the Emergency Department. Annals of Emergency Medicine, 2011, 57, 31-32.	0.3	28
298	Variation in Management of Recent-Onset Atrial Fibrillation and Flutter Among Academic Hospital Emergency Departments. Annals of Emergency Medicine, 2011, 57, 13-21.	0.3	111
299	To Shock or Not to Shock: That is the Question; is There an Answer?. Annals of Emergency Medicine, 2011, 57, 22-23.	0.3	2
300	To Shock or Not to Shock: That is the Question; Is There an Answer?. Annals of Emergency Medicine, 2011, 57, 694-702.	0.3	0
301	Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. Future Cardiology, 2011, 7, 415-423.	0.5	6
304	Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. European Journal of Heart Failure, 2011, 13, 1111-1120.	2.9	119
305	Incidence and clinical relevance of uncontrolled ventricular rate during atrial fibrillation in heart failure patients treated with cardiac resynchronization therapy. European Journal of Heart Failure, 2011, 13, 868-876.	2.9	53
306	The Impact of Comorbidities on Stroke Prophylaxis Strategies in Atrial Fibrillation Patients. American Journal of Therapeutics, 2011, 18, 510-517.	0.5	2
307	Atrial Fibrillation. Circulation, 2011, 124, 95-99.	1.6	10
308	Rate Control in Atrial Fibrillation. Circulation, 2011, 124, 2746-2755.	1.6	41
309	Effects of a Highly Selective Acetylcholine-Activated K ⁺ Channel Blocker on Experimental Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 94-102.	2.1	78
310	Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand. Cardiology Research and Practice, 2011, 2011, 1-10.	0.5	2
311	Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace, 2011, 13, 1517-1525.	0.7	55
312	2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating) Tj ETQq	1 1.0.784: 1.8	314 rgBT /0\ 618
313	A New Landscape for Stroke Prevention in Atrial Fibrillation. Stroke, 2011, 42, 3316-3322.	1.0	26
314	Role of cardiac resynchronization therapy and atrioventricular junction ablation in patients with permanent atrial fibrillation. European Heart Journal, 2011, 32, 2344-2346.	1.0	3
315	Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace, 2011, 13, 329-345.	0.7	202
316	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace, 2011, 13, 1118-1126.	0.7	33

#	Article	IF	CITATIONS
317	Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace, 2011, 13, 1368-1374.	0.7	25
318	Individual dosage of digoxin in patients with heart failure. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 309-317.	0.2	12
319	Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace, 2011, 13, 161-173.	0.7	140
320	Atrial fibrillation in elderly patients with heart failure: convergence of two cardiovascular epidemics in the 21st Century. Expert Review of Cardiovascular Therapy, 2011, 9, 903-912.	0.6	1
321	Atrial Fibrillation Pathophysiology. Circulation, 2011, 124, 2264-2274.	1.6	646
322	Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter. Clinical Medicine Insights: Cardiology, 2011, 5, CMC.S6677.	0.6	33
323	Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. Physiological Reviews, 2011, 91, 265-325.	13.1	1,048
324	Management of Patients with Atrial Fibrillation: Specific Considerations for the Old Age. Cardiology Research and Practice, 2011, 2011, 1-8.	0.5	3
326	Atrioventricular Nodal Ablation in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 68-76.	2.1	84
327	Current Issues in Atrial Fibrillation. ISRN Cardiology, 2012, 2012, 1-10.	1.6	0
328	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
329	Management Strategies in Atrial Fibrillation in Patients With Heart Failure. Cardiology in Review, 2012, 20, 288-296.	0.6	3
330	Does catheter ablation for atrial fibrillation increase or reduce neurological insult?. Current Opinion in Cardiology, 2012, 27, 36-40.	0.8	3
331	Management of atrial fibrillation in the acute setting. Current Opinion in Critical Care, 2012, 18, 333-340.	1.6	4
332	Mineralocorticoid Receptor Antagonists and Mortality in Heart Failure With Concurrent Atrial Fibrillation. Circulation: Heart Failure, 2012, 5, 550-551.	1.6	4
333	Advances in the management of atrial fibrillation. Clinical Medicine, 2012, 12, 544-552.	0.8	0
335	Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation. Expert Review of Clinical Pharmacology, 2012, 5, 163-171.	1.3	3

	Сп	TATION REPORT	
# 337	ARTICLE Review of Contemporary Antiarrhythmic Drug Therapy for Maintenance of Sinus Rhythm in Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2012, 17, 12-20.	IF 1.0	CITATIONS
338	Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart, 2012, 98, 48-53.	1.2	163
339	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart, 2012, 98, 195-201.	1.2	109
340	Rate vs Rhythm Control in Atrial Fibrillation. Archives of Internal Medicine, 2012, 172, 983-4.	4.3	2
341	Irregular Rhythm Adversely Influences Calcium Handling in Ventricular Myocardium. Circulation: Heart Failure, 2012, 5, 786-793.	1.6	59
342	Mineralocorticoid Receptor Antagonists and Cardiovascular Mortality in Patients With Atrial Fibrillation and Left Ventricular Dysfunction. Circulation: Heart Failure, 2012, 5, 586-593.	1.6	15
343	Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace, 2012, 14, 666-674.	0.7	114
344	Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates. Canadian Journal of Emergency Medicine, 2012, 14, 169-177.	0.5	9
345	Atrial Fibrillation in Heart Failure: An Innocent Bystander?. Current Cardiology Reviews, 2012, 8, 273-280.	0.6	7
346	Novel Anti-arrhythmic Medications in the Treatment of Atrial Fibrillation. Current Cardiology Reviews, 2012, 8, 302-309.	0.6	13
347	The ups and downs of heart rate. Critical Care Medicine, 2012, 40, 239-245.	0.4	59
348	Stroke Prevention in Atrial Fibrillation: Concepts and Controversies. Current Cardiology Reviews, 2012, 8, 290-301.	0.6	12
349	Medical treatment of atrial fibrillation. Journal of Cardiovascular Medicine, 2012, 13, 97-107.	0.6	20
351	Atrial fibrillation. Lancet, The, 2012, 379, 648-661.	6.3	337
352	Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet, The, 2012, 380, 238-246.	6.3	141
353	Examining the safety of amiodarone. Expert Opinion on Drug Safety, 2012, 11, 191-214.	1.0	56
354	Anxiety Sensitivity Moderates Prognostic Importance of Rhythm-Control Versus Rate-Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure. Circulation: Heart Failure, 2012, 5, 322-330.	1.6	23
356	A Common β1-Adrenergic Receptor Polymorphism Predicts Favorable Response to Rate-Control Thera in Atrial Fibrillation. Journal of the American College of Cardiology, 2012, 59, 49-56.	ру 1.2	84

			2
#	Article	IF	CITATIONS
357	Cardiac arrhythmiasâ \in "trials and tribulations. Lancet, The, 2012, 380, 1448-1451.	6.3	1
358	Adverse effects of permanent atrial fibrillation on heart failure in patients with preserved left ventricular function and chronic right apical pacing for complete heart block. Clinical Research in Cardiology, 2012, 101, 829-836.	1.5	8
359	Should rhythm control be preferred in younger atrial fibrillation patients?. Journal of Interventional Cardiac Electrophysiology, 2012, 35, 71-80.	0.6	8
360	New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed), 2012, 65, 7-13.	0.4	1
361	Comparison of Circumferential Pulmonary Vein Isolation and Antiarrhythmic Drug Therapy in Patients with Atrial Fibrillation. Cardiology and Therapy, 2012, 1, 3.	1.1	1
362	Acute Management of Atrial Fibrillation. Cardiology Clinics, 2012, 30, 567-589.	0.9	8
363	2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. Heart Rhythm, 2012, 9, 632-696.e21.	0.3	1,541
364	Evaluation of the impact of atrial fibrillation on rehospitalization events in heart failure patients in recent years. Journal of Cardiology, 2012, 60, 36-41.	0.8	8
365	Association between clinical outcome and antiarrhythmic treatment in heart failure patients who have atrial fibrillation upon admission to the hospital. Journal of Cardiology, 2012, 60, 31-35.	0.8	4
366	A review of the epidemiological profile of patients with atrial fibrillation and heart failure. Expert Review of Cardiovascular Therapy, 2012, 10, 1133-1140.	0.6	8
367	Fine-Tuning a Heart-Brain Connection. Circulation: Heart Failure, 2012, 5, 307-308.	1.6	6
368	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
369	Nuevas evidencias, nuevas controversias: análisis crÃtico de la guÃa de práctica clÃnica sobre fibrilación auricular 2010 de la Sociedad Europea de CardiologAa. Revista Espanola De Cardiologia, 2012, 65, 7-13.	0.6	26
370	Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. American Heart Journal, 2012, 163, 887-893.	1.2	88
371	A New Scoring System for Evaluating the Risk of Heart Failure Events in Japanese Patients With Atrial Fibrillation. American Journal of Cardiology, 2012, 110, 678-682.	0.7	36
372	Managing Emergency Department Patients with Recent-onset Atrial Fibrillation. Journal of Emergency Medicine, 2012, 42, 139-148.	0.3	37
373	Long term treatment of atrial fibrillation in elderly patients: A decision analysis. International Journal of Cardiology, 2012, 155, 102-109.	0.8	2
374	Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits. International Journal of Cardiology, 2012, 155, 362-371.	0.8	58

#	ARTICLE	IF	CITATIONS
375	Management of Atrial Fibrillation in Patients With Structural Heart Disease. Circulation, 2012, 125, 945-957.	1.6	106
376	Augmented singleâ€unit muscle sympathetic nerve activity in heart failure with chronic atrial fibrillation. Journal of Physiology, 2012, 590, 509-518.	1.3	31
377	Role of New Drugs for Management of Atrial Fibrillation. Annals of Pharmacotherapy, 2012, 46, 1656-1670.	0.9	2
378	Comparative Effectiveness of Rhythm Control vs Rate Control Drug Treatment Effect on Mortality in Patients With Atrial Fibrillation. Archives of Internal Medicine, 2012, 172, 997-1004.	4.3	126
379	The Role of Anticoagulation in a Patient with Atrial Fibrillation and a CHADS2 Score of 1. Cardiac Electrophysiology Clinics, 2012, 4, 107-117.	0.7	1
380	Transforming the Emergency Department Observation Unit. Cardiology Clinics, 2012, 30, 501-521.	0.9	14
381	Atrial Fibrillation Ablation and Heart Failure. Current Cardiology Reports, 2012, 14, 571-576.	1.3	6
382	Rate versus rhythm control in atrial fibrillation and clinical outcomes: Updated systematic review and meta-analysis of randomized controlled trials. Archives of Cardiovascular Diseases, 2012, 105, 226-238.	0.7	63
383	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. American Heart Journal, 2012, 164, 616-624.	1.2	45
384	Rate or Rhythm Control for Atrial Fibrillation: Update and Controversies. American Journal of Medicine, 2012, 125, 1049-1056.	0.6	21
385	Thirty-Day and 1-Year Outcomes of Emergency Department Patients With Atrial Fibrillation and No Acute Underlying Medical Cause. Annals of Emergency Medicine, 2012, 60, 755-765.e2.	0.3	42
386	In Silico Optimization of Atrial Fibrillation-Selective Sodium Channel Blocker Pharmacodynamics. Biophysical Journal, 2012, 102, 951-960.	0.2	25
387	Outcomes after stepwise ablation for persistent atrial fibrillation in patients with heart failure. Journal of Arrhythmia, 2012, 28, 347-352.	0.5	4
389	Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Archives of Internal Medicine, 2012, 172, 623.	4.3	139
390	Atrial Fibrillation in Heart Failure. Current Heart Failure Reports, 2012, 9, 309-318.	1.3	8
391	Atrial Fibrillation Management in Elderly. Current Cardiovascular Risk Reports, 2012, 6, 431-442.	0.8	1
392	GuÃa de práctica clÃnica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	0.6	31
393	Atrial Fibrillation in Heart Failure. Medical Clinics of North America, 2012, 96, 987-1000.	1.1	19

#	Article	IF	CITATIONS
394	Managing atrial fibrillation in the CRT patient: Controversy or consensus?. Heart Rhythm, 2012, 9, S51-S59.	0.3	12
395	Real-life global survey evaluating patients with atrial fibrillation (REALISE-AF): results of an international observational registry. Expert Review of Cardiovascular Therapy, 2012, 10, 283-291.	0.6	28
396	Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation. Internal and Emergency Medicine, 2012, 7, 241-250.	1.0	3
397	Atrial Fibrillation and Atrial Flutter. Clinics in Geriatric Medicine, 2012, 28, 635-647.	1.0	2
398	Narrative Review. Journal of Intensive Care Medicine, 2012, 27, 343-353.	1.3	11
399	Atrial fibrillation 3: management. Practice Nursing, 2012, 23, 120-128.	0.1	0
400	Cardiac Arrhythmias with Supraventricular Origin. , 2012, , 348-359.		1
402	Costs and clinical consequences of suboptimal atrial fibrillation management. ClinicoEconomics and Outcomes Research, 2012, 4, 79.	0.7	11
403	Estudo transversal das estratégias de tratamento clÃnico na fibrilação atrial. Arquivos Brasileiros De Cardiologia, 2012, 98, 195-202.	0.3	6
404	Benefitâ€Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation. Clinical Cardiology, 2012, 35, 28-32.	0.7	3
405	Systematic Review and Meta-analysis of the Efficacy of Cardioversion by Vernakalant and Comparators in Patients with Atrial Fibrillation. Cardiovascular Drugs and Therapy, 2012, 26, 167-179.	1.3	58
406	Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews, 2012, 17, 597-613.	1.7	38
407	A randomized trial of budiodarone in paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 1-9.	0.6	24
408	Continuous versus Intermittent Monitoring of Ventricular Rate in Patients with Permanent Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 598-604.	0.5	10
409	Impact of Catheter Ablation on Quality of Life in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2012, 23, 128-129.	0.8	1
410	Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 431-435.	0.7	11
411	Atrial fibrillation, stroke, and quality of life. Annals of the New York Academy of Sciences, 2012, 1254, 140-150.	1.8	18
413	Heart failure, diastolic dysfunction and atrial fibrillation; mechanistic insight of a complex inter-relationship. Heart Failure Reviews, 2012, 17, 27-33.	1.7	24

#	Article	IF	CITATIONS
415	Catheter ablation of atrial fibrillation in the elderly: does the benefit outweigh the risk?. Expert Review of Cardiovascular Therapy, 2013, 11, 697-704.	0.6	19
416	Outcome prediction in heart failure with atrial fibrillation: Relative role of left ventricular ejection fraction and neurohormonal measures. Journal of Nuclear Cardiology, 2013, 20, 821-829.	1.4	1
417	Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18–19, 2012, Belo Horizonte, Minas Gerais, Brazil. Journal of Thrombosis and Thrombolysis, 2013, 36, 115-130.	1.0	0
418	Benefit-Risk Assessment of Dronedarone in the Treatment of Atrial Fibrillation. Drug Safety, 2013, 36, 93-110.	1.4	8
419	Management of Atrial Fibrillation in the Year 2033: NewÂConcepts, Tools, and Applications Leading to Personalized Medicine. Canadian Journal of Cardiology, 2013, 29, 1141-1146.	0.8	33
420	Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach. Acta Diabetologica, 2013, 50, 827-835.	1.2	14
421	Heart Failure, Atrial Fibrillation, and Catheter Ablation. Journal of the American College of Cardiology, 2013, 61, 1904-1905.	1.2	3
422	Common Threads in Atrial Fibrillation and Heart Failure. Heart Failure Clinics, 2013, 9, 373-383.	1.0	8
423	Digoxin significantly improves all-cause mortality in atrial fibrillation patients with severely reduced left ventricular systolic function. International Journal of Cardiology, 2013, 169, e84-e86.	0.8	30
424	Does Chronic Atrial Fibrillation Induce Cardiac Remodeling?. Echocardiography, 2013, 30, 140-146.	0.3	6
425	2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation, 2013, 128, e240-327.	1.6	2,335
426	Cardiac remodeling with rhythm versus rate control strategies for atrial fibrillation in patients with heart failure: Insights from the AF-CHF echocardiographic sub-study. International Journal of Cardiology, 2013, 165, 430-436.	0.8	13
427	Case Selection for Cardiac Resynchronization in Atrial Fibrillation. Heart Failure Clinics, 2013, 9, 461-474.	1.0	14
428	Ventricular Rate Control of Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 397-406.	1.0	6
429	Surgical Treatment of Atrial Fibrillation in the Heart Failure Population. Heart Failure Clinics, 2013, 9, 533-539.	1.0	0
430	Acute Exposure to Air Pollution Triggers Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 816-825.	1.2	168
431	Rate versus rhythm control for management of atrial fibrillation in clinical practice: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. American Heart Journal, 2013, 165, 622-629.	1.2	61
432	Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. International Journal of Cardiology, 2013, 164, 21-32.	0.8	29

ARTICLE IF CITATIONS # Cardioversion for atrial fibrillation in current European practice: results of the European Heart 433 0.7 38 Rhythm Association survey. Europace, 2013, 15, 915-918. Antiarrhythmic Drugs 2013: State of the Art. Current Cardiology Reports, 2013, 15, 410. 434 1.3 Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: 435 0.8 13 Prospective non-interventional study. International Journal of Cardiology, 2013, 167, 750-756. Antiarrhythmic Drugs in Atrial Fibrillation: Do They Have a Future?. Canadian Journal of Cardiology, 2013, 29, 1158-1164. Atrial Fibrillation and Congestive Heart Failure: A Cost Analysis of Rhythm-Control vs Rate-Control 437 0.8 10 Strategies. Canadian Journal of Cardiology, 2013, 29, 1256-1262. Rate control in atrial fibrillation, insight into the RACE II study. Netherlands Heart Journal, 2013, 21, 0.3 199-204. Increased mortality among patients taking digoxin--analysis from the AFFIRM study. European Heart 440 1.0 239 Journal, 2013, 34, 1481-1488. Quality of Life and Functional Capacity in Patients With Atrial Fibrillation and Congestive Heart 1.2 Failure. Journal of the American College of Cardiology, 2013, 61, 455-460. 442 Atrial Fibrillation Through the Years. Circulation, 2013, 127, 408-416. 1.6 12 The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on 443 0.8 176 Acute and Chronic Heart Failure. Canadian Journal of Cardiology, 2013, 29, 168-181. Pharmacologic Rate versus Rhythmâ€Control Strategies in Atrial Fibrillation: An Updated 444 0.5 90 Comprehensive Review and Metaâ€Analysis. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 122-133. Therapeutic Effects of Selective Atrioventricular Node Vagal Stimulation in Atrial Fibrillation and 0.8 Heart Failure. Journal of Cardiovascular Electrophysiology, 2013, 24, 86-91. AV Nodal Fat Pad Stimulation for Rate Control in Atrial Fibrillation and Heart Failure: A Better 446 0.8 1 Solution?. Journal of Cardiovascular Electrophysiology, 2013, 24, 92-93. Heart Rate Control in Patients With Chronic Atrial Fibrillation and Heart Failure. Congestive Heart 447 Failure, 2013, 19, 25-28. 448 Stroke Prevention in Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 427-435. 1.0 2 Improving outcomes in patients with atrial fibrillation: Rationale and design of the Early treatment of 449 1.2 132 Atrial fibrillation for Stroke prevention Trial. American Heart Journal, 2013, 166, 442-448. Atrial flutter and fibrillation in patients with pulmonary hypertension. International Journal of 451 0.8 153 Cardiology, 2013, 167, 2300-2305. Catheter Ablation of Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 515-532.

#	Article	IF	CITATIONS
453	Reply. Journal of the American College of Cardiology, 2013, 61, 2197.	1.2	6
454	Impact of Atrial Fibrillation on Outcomes in Heart Failure. Heart Failure Clinics, 2013, 9, 437-449.	1.0	2
455	Atrial Fibrillation in Heart Failure in the Older Population. Heart Failure Clinics, 2013, 9, 451-459.	1.0	6
456	A Critical Perspective on the Role of Catheter Ablation in Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2013, 29, 1150-1157.	0.8	8
457	The Potential Role of Nonpharmacologic Electrophysiology-Based Interventions in Improving Outcomes in Patients Hospitalized for Heart Failure. Heart Failure Clinics, 2013, 9, 331-343.	1.0	0
458	Psychological Distress and Arrhythmia: Risk Prediction and Potential Modifiers. Progress in Cardiovascular Diseases, 2013, 55, 582-589.	1.6	58
459	A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings, 2013, 88, 790-798.	1.4	300
460	Direct or Coincidental Elimination of Stable Rotors or Focal Sources May Explain Successful Atrial Fibrillation Ablation. Journal of the American College of Cardiology, 2013, 62, 138-147.	1.2	214
463	The Role of Ablation of the Atrioventricular Junction in Patients with Heart Failure and Atrial Fibrillation. Heart Failure Clinics, 2013, 9, 489-499.	1.0	1
464	Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillation. American Heart Journal, 2013, 166, 871-878.	1.2	12
465	Fish Oil and Post-Operative Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2194-2196.	1.2	52
466	A Randomized Trial to Assess Catheter Ablation Versus Rate Control in the Management of Persistent Atrial Fibrillation in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1894-1903.	1.2	390
467	Statins and atrial fibrillation in patients with left ventricular dysfunction: Insights from the AF-CHF trial. International Journal of Cardiology, 2013, 165, 575-577.	0.8	6
468	Aggressive approach and outcome in patients presenting atrial fibrillation and hypertension. International Journal of Cardiology, 2013, 166, 50-54.	0.8	5
469	Rhythm Control of Atrial Fibrillation in Heart Failure. Heart Failure Clinics, 2013, 9, 407-415.	1.0	10
470	Review of epidemiology and management of atrial fibrillation in developing countries. International Journal of Cardiology, 2013, 167, 2412-2420.	0.8	106
471	Clinical <scp>U</scp> pdate on the <scp>M</scp> anagement of <scp>A</scp> trial <scp>F</scp> ibrillation. Pharmacotherapy, 2013, 33, 422-446.	1.2	15
473	Improving Quality of Life and Functional Capacity in Atrial Fibrillation and Congestive Heart Failure.	1.2	0

# 474	ARTICLE Treatment Targets in Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 461-462.	IF 1.2	Citations 0
475	2013 ACCF/AHA Guideline for the Management of HeartÂFailure. Journal of the American College of Cardiology, 2013, 62, e147-e239.	1.2	7,017
476	Atrial Fibrillation in the Elderly. Drugs and Aging, 2013, 30, 593-601.	1.3	29
477	Atrial Fibrillation and Stroke: The Evolving Role of Rhythm Control. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 299-312.	0.4	1
478	Practice Implications of the Atrial Fibrillation Guidelines. American Journal of Cardiology, 2013, 111, 1660-1670.	0.7	11
480	The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology, 2013, 62, 2433-2447.	1.2	1
481	Atrial fibrillation is associated with increased mortality: causation or association?. European Heart Journal, 2013, 34, 1027-1030.	1.0	40
482	Catheter ablation versus rate control for atrial fibrillation: what have we learnt from the ARC-HF trial?. Future Cardiology, 2013, 9, 599-602.	0.5	1
483	Addressing the Controversy of Rate Versus Rhythm Control in Atrial Fibrillation. Postgraduate Medicine, 2013, 125, 7-18.	0.9	101
484	Recent advances in management of atrial fibrillation in patients with heart failure. Current Opinion in Cardiology, 2013, 28, 197-208.	0.8	5
485	Atrial fibrillation and heart failure. Current Opinion in Cardiology, 2013, 28, 332-336.	0.8	4
486	Comparative effectiveness of antiarrhythmic drugs on cardiovascular hospitalization and mortality in atrial fibrillation. Journal of Comparative Effectiveness Research, 2013, 2, 301-312.	0.6	2
487	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. Circulation, 2013, 128, 2192-2201.	1.6	268
488	New Oral Anticoagulants in Atrial Fibrillation Forever?. Circulation, 2013, 128, 200-202.	1.6	5
489	Atrial Fibrillation and Heart Failure: Rate Versus Rhythm Control. , 2013, , 129-144.		0
491	Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction. Circulation, 2013, 128, 1085-1093.	1.6	276
492	Letter by Parikh and Rashba Regarding Article, "Rhythm Versus Rate Control Therapy and Subsequent Stroke or Transient Ischemic Attack in Patients With Atrial Fibrillation― Circulation, 2013, 128, e42.	1.6	0
493	Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The <scp>RealiseAF</scp> Survey. Clinical Cardiology, 2013, 36, 766-774.	0.7	23

#	Article	IF	CITATIONS
494	Adding serial Nâ€ŧerminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar) Tj ETQq0 0 0 rgBT /Over	lo zk 910 Tf	5 0 2737 Td (1
495	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. European Journal of Heart Failure, 2013, 15, 324-333.	2.9	33
496	Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a postâ€hoc analysis of the RACE II study. European Journal of Heart Failure, 2013, 15, 1311-1318.	2.9	88
497	Acute Rate Control in Atrial Fibrillation With Left Ventricular Dysfunction. Circulation Journal, 2013, 77, 893-894.	0.7	4
498	Catheter ablation for atrial fibrillation in the elderly. Clinical Practice (London, England), 2013, 10, 493-502.	0.1	0
499	Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study. Patient Preference and Adherence, 2013, 7, 835.	0.8	4
500	Impact of Emergency Department Management of Atrial Fibrillation on Hospital Charges. Western Journal of Emergency Medicine, 2013, 14, 55-57.	0.6	19
501	Update on the management of atrial fibrillation. Medical Journal of Australia, 2013, 199, 592-597.	0.8	19
502	DOES TREATMENT STRATEGY FOR ATRIAL FIBRILLATION INFLUENCE MYOCARDIAL CONTRACTILE FUNCTION?. Rational Pharmacotherapy in Cardiology, 2013, 9, 619-626.	0.3	1
503	Current Status of Rate Control for Clinical Management of Patients with Atrial Fibrillation. Japanese Journal of Electrocardiology, 2014, 33, 458-465.	0.0	0
504	Role of digoxin in controlling the ventricular rate during atrial fibrillation: a systematic review and a rethinking. Research Reports in Clinical Cardiology, 0, , 93.	0.2	3
505	Rotors in Human Atrial Fibrillation. , 2014, , 433-442.		0
506	Clinical Characteristics, Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey. PLoS ONE, 2014, 9, e86443.	1.1	9
507	Medicina Interna e Clinical Governance: quali proposte per il prossimo futuro?. Italian Journal of Medicine, 2014, 2, 71.	0.2	0
508	CHANGE OF LOCAL MYOCARDIAL CONTRACTILITY DUE TO SELECTION OF DIFFERENT ARRHYTHMIA TREATMENT STRATEGIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND PAROXYSMAL ATRIAL FIBRILLATION. Rational Pharmacotherapy in Cardiology, 2014, 10, 160-165.	0.3	1
509	FEATURES OF THE CARDIOVERSION IN ATRIAL FLUTTER AND FIBRILLATION IN ERA OF NEW ANTICOAGULANTS: PRACTICAL CARDIOLOGIST VIEW. Rational Pharmacotherapy in Cardiology, 2014, 10, 416-420.	0.3	0
510	Efficacy of Amiodarone in Patients with Atrial Fibrillation with and without Left Ventricular Dysfunction: A Pooled Analysis of AFFIRM and AF HF Trials. Journal of Cardiovascular Electrophysiology, 2014, 25, 1306-1313.	0.8	21
511	Neurologic complications of cardiomyopathies and other myocardial disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 119, 111-128.	1.0	3

#	Article	IF	CITATIONS
512	Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 123-130.	1.6	134
513	Investigation of arrhythmia: recording and interpreting an electrocardiogram. Companion Animal, 2014, 19, 355-363.	0.0	0
514	Avoid Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy. Cardiology, 2014, 127, 51-52.	0.6	0
515	The validity and reliability of the Turkish version of the University of Toronto Atrial Fibrillation Severity Scale. Turkish Journal of Medical Sciences, 2014, 44, 996-1001.	0.4	3
516	Slowing down the heart rate in permanent atrial fibrillation. European Heart Journal, 2014, 35, 480-481.	1.0	3
517	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace, 2014, 16, 174-181.	0.7	29
518	Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease. Europace, 2014, 16, 153-155.	0.7	0
519	Effects of Atrioventricular Nodal Ablation on Permanent Atrial Fibrillation Patients With Cardiac Resynchronization Therapy: A Systematic Review and Metaâ€analysis. Clinical Cardiology, 2014, 37, 707-715.	0.7	33
520	Predictive value of the heart rate reserve in patients with permanent atrial fibrillation treated according to a strict rate-control strategy. Europace, 2014, 16, 1125-1130.	0.7	6
521	Systolic blood pressure and mortality in patients with atrial fibrillation and heart failure: insights from the <scp>AFFIRM</scp> and <scp>AFâ€CHF</scp> studies. European Journal of Heart Failure, 2014, 16, 1168-1174.	2.9	16
522	Initial Independent Outcomes from Focal Impulse and Rotor Modulation Ablation for Atrial Fibrillation: Multicenter FIRM Registry. Journal of Cardiovascular Electrophysiology, 2014, 25, 921-929.	0.8	179
523	What Tissue Does Circumferential PV Isolation Actually Modulate?. Journal of Cardiovascular Electrophysiology, 2014, 25, 119-121.	0.8	1
524	How much atrial fibrillation causes symptoms of heart failure?. International Journal of Clinical Practice, 2014, 68, 453-457.	0.8	2
525	Clinical characteristics and outcomes in superâ€elderly patients (>85 years) with heart failure: single center observational study in <scp>J</scp> apan. Acute Medicine & Surgery, 2014, 1, 76-82.	0.5	5
526	Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 896-904.	0.9	52
527	Impact of Atrial Fibrillation on Healthcare Utilization in the Community: The Atherosclerosis Risk in Communities Study. Journal of the American Heart Association, 2014, 3, e001006.	1.6	25
528	Informed Choice of Composite End Points in Cardiovascular Trials. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 170-178.	0.9	21
529	Management of Atrial Fibrillation in Critically Ill Patients. Critical Care Research and Practice, 2014, 2014, 1-10.	0.4	45

#	Article	IF	CITATIONS
530	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation, 2014, 130, e199-267.	1.6	3,471
531	Atrial Fibrillation Is an Independent Risk Factor for Ventricular Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 1033-1039.	2.1	47
532	Role of left atrial speckle tracking echocardiography in predicting persistent atrial fibrillation electrical cardioversion success and sinus rhythm maintenance at 6 months. Advances in Medical Sciences, 2014, 59, 120-125.	0.9	8
533	Does Digoxin Increase the Risk of Ischemic Stroke and Mortality in Atrial Fibrillation? A Nationwide Population-Based Cohort Study. Canadian Journal of Cardiology, 2014, 30, 1190-1195.	0.8	39
534	Profile of CZECH AF 2012. Profile of atrial fibrillation patients receiving antithrombotic therapy. Cor Et Vasa, 2014, 56, e207-e216.	0.1	3
535	Atrial Fibrillation and Sudden Cardiac Death. JACC: Heart Failure, 2014, 2, 228-229.	1.9	7
536	Atrial fibrillation in heart failure: drug therapies for rate and rhythm control. Heart Failure Reviews, 2014, 19, 315-324.	1.7	11
537	Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure. Heart and Vessels, 2014, 29, 464-469.	0.5	21
539	Left atrial mechanics predict the success of pulmonary vein isolation in patients with atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2014, 40, 53-62.	0.6	20
540	A Randomized Controlled Trial of Catheter Ablation Versus Medical Treatment of Atrial Fibrillation in Heart Failure (The CAMTAF Trial). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 31-38.	2.1	387
541	2014 AHA/ACC/HRS Guideline forÂtheÂManagement of Patients WithÂAtrial Fibrillation. Journal of the American College of Cardiology, 2014, 64, e1-e76.	1.2	3,332
542	Prognostic Value of the Physical Examination in Patients With Heart Failure and Atrial Fibrillation. JACC: Heart Failure, 2014, 2, 15-23.	1.9	29
543	Long-term follow-up after atrial fibrillation ablation in patients with impaired left ventricular systolic function: The importance of rhythm and rate control. Heart Rhythm, 2014, 11, 344-351.	0.3	69
544	Atrial Tachyarrhythmias Temporally Precede Fluid Accumulation in Implantable Device Patients. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 554-561.	0.5	4
545	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. Circulation, 2014, 129, 1568-1576.	1.6	324
546	Cardiac MRI assessment of atrial fibrosis in atrial fibrillation: implications for diagnosis and therapy. Heart, 2014, 100, 590-596.	1.2	42
547	Prognosis in Patients Hospitalized With Permanent and Nonpermanent Atrial Fibrillation in Heart Failure. American Journal of Cardiology, 2014, 113, 1189-1195.	0.7	19
548	2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary. Circulation, 2014, 130, 2071-2104.	1.6	1,803

#	Article	IF	CITATIONS
549	Atrial Fibrillation Ablation Outcome Is Predicted by Left Atrial Remodeling on MRI. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 23-30.	2.1	316
550	Atrial Fibrillation Therapy. , 2014, , .		3
551	Atrial Fibrillation and Heart Failure: Cause or Effect?. Current Heart Failure Reports, 2014, 11, 463-470.	1.3	15
552	Challenging the status quo: β-blockers for HF plus AF. Nature Reviews Cardiology, 2014, 11, 690-692.	6.1	6
553	Fibroblast Electrical Remodeling in Heart Failure and Potential Effects on Atrial Fibrillation. Biophysical Journal, 2014, 107, 2444-2455.	0.2	38
554	Maybe Atrial Fibrillation DOES Matter in Ventricular Assist Device Patients?â^—. Journal of the American College of Cardiology, 2014, 64, 1891-1893.	1.2	0
555	Antiarrhythmic Drug Therapy for Atrial Fibrillation. Cardiology Clinics, 2014, 32, 533-549.	0.9	6
556	Rate Versus Rhythm Control for Atrial Fibrillation. Cardiology Clinics, 2014, 32, 521-531.	0.9	2
557	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. Canadian Journal of Cardiology, 2014, 30, e1-e63.	0.8	200
559	Frequency of Supraventricular Arrhythmias in Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Cardiology, 2014, 114, 1420-1425.	0.7	54
560	Cardiac fibrillation—challenges and evolving solutions. Nature Reviews Cardiology, 2014, 11, 626-627.	6.1	4
561	Atrial Fibrillation: Antiarrhythmic Therapy. Current Problems in Cardiology, 2014, 39, 351-391.	1.1	6
562	Practical Management of Postoperative Atrial Fibrillation after Noncardiac Surgery. Journal of the American College of Surgeons, 2014, 219, 831-841.	0.2	56
563	Rhythm Control in Heart Failure Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2014, 64, 710-721.	1.2	71
564	2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, e153-e193.	0.4	236
565	Diagnosis and Management of Atrial Fibrillation: An Overview. Cardiovascular Therapeutics, 2014, 32, 242-252.	1.1	6
566	The Clinical Profile and Pathophysiology of Atrial Fibrillation. Circulation Research, 2014, 114, 1453-1468.	2.0	899
567	Atrial Fibrillation Therapy Now and in the Future. Circulation Research, 2014, 114, 1532-1546.	2.0	100

#	Article	IF	CITATIONS
568	The Impact of Heart Failure and Left Ventricular Dysfunction in Predicting Stroke, Thromboembolism, and Mortality in Atrial Fibrillation Patients: A Systematic Review. Clinical Therapeutics, 2014, 36, 1135-1144.	1.1	57
569	Current Approaches to Antiarrhythmic Therapy in Heart Failure. Heart Failure Clinics, 2014, 10, 635-652.	1.0	4
570	Evaluation of Time Course and Predicting Factors of Progression of Paroxysmal or Persistent Atrial Fibrillation to Permanent Atrial Fibrillation. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 345-355.	0.5	27
571	Combined management of atrial fibrillation and heart failure: case studies. Heart Failure Reviews, 2014, 19, 331-339.	1.7	1
572	Atrial fibrillation in heart failure: catheter and surgical interventional therapies. Heart Failure Reviews, 2014, 19, 325-330.	1.7	8
573	Rotors as Drivers of Atrial Fibrillation and Targets for Ablation. Current Cardiology Reports, 2014, 16, 509.	1.3	26
574	Arrhythmias in Structural Heart Disease. Current Cardiology Reports, 2014, 16, 510.	1.3	7
575	Relationship between cardiopulmonary exercise testing parameters and heart failure risk (H2ARDD) Tj ETQq1 1 0	.784314 r	gBT /Overloc
576	Rationale and design of PRIMA II: A multicenter, randomized clinical trial to study the impact of in-hospital guidance for acute decompensated heart failure treatment by a predefined NT-PRoBNP target on the reduction of readmIssion and Mortality rAtes. American Heart Journal, 2014, 168, 30-36.	1.2	36
577	PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease. Heart Rhythm, 2014, 11, e102-e165.	0.3	585
578	Trends in the pharmacologic management of atrial fibrillation: Data from the Veterans Affairs health system. American Heart Journal, 2014, 168, 53-59.e1.	1.2	11
579	Contemporary Trends of Hospitalization for Atrial Fibrillation in the United States, 2000 Through 2010. Circulation, 2014, 129, 2371-2379.	1.6	365
580	Early management of atrial fibrillation to prevent cardiovascular complications. European Heart Journal, 2014, 35, 1448-1456.	1.0	190
581	Update on atrial fibrillation. Egyptian Heart Journal, 2014, 66, 193-216.	0.4	5
582	Ablation of Rotor and Focal Sources Reduces Late Recurrence of Atrial Fibrillation Compared With Trigger Ablation Alone. Journal of the American College of Cardiology, 2014, 63, 1761-1768.	1.2	354
583	Atrial Fibrillation and Congestive Heart Failure. Heart Failure Clinics, 2014, 10, 305-318.	1.0	19
584	Rotors and Focal Sources for Human Atrial Fibrillation. Circulation Journal, 2014, 78, 2357-2366.	0.7	8
585	The Value of Magnetic Resonance Imaging in Catheter Ablation of Atrial Fibrillation. Clinical	0.7	4

# 586	ARTICLE An International Observational Prospective Survey Assessing the Control of Atrial Fibrillation in Asia-Pacific: Results of the Record-AFAP Registry. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S22022.	IF 0.6	Citations
587	Atrial fibrillation ablation and left appendage closure in heart failure patients. Current Opinion in Cardiology, 2015, 30, 259-266.	0.8	3
588	The Past, Present, and Potential Future of Sodium Channel Block as an Atrial Fibrillation Suppressing Strategy. Journal of Cardiovascular Pharmacology, 2015, 66, 432-440.	0.8	15
589	Treatment Failure With Rhythm and Rate Control Strategies in Patients With Atrial Fibrillation and Congestive Heart Failure: An AFâ€CHF Substudy. Journal of Cardiovascular Electrophysiology, 2015, 26, 1327-1332.	0.8	7
590	Atrial Fibrillation: Mechanisms, Therapeutics, and Future Directions. , 2015, 5, 649-665.		96
591	Catheter ablation of atrial fibrillation in patients with heart failure: can we break the vicious circle?. European Journal of Heart Failure, 2015, 17, 1003-1005.	2.9	7
592	Autophagy in the Onset of Atrial Fibrillation. , 2015, , 193-201.		0
593	Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World Journal of Cardiology, 2015, 7, 808.	0.5	35
594	The first Russian register of patients with chronic heart failure and atrial fibrillation (RIF-CHF): study design. Rational Pharmacotherapy in Cardiology, 2015, 11, 577-581.	0.3	10
595	Tachycardia-Induced Cardiomyopathy. , 0, , .		0
596	Managing atrial fibrillation in the very elderly patient: challenges and solutions. Vascular Health and Risk Management, 2015, 11, 555.	1.0	47
597	How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?. Current Cardiology Reviews, 2015, 11, 190-198.	0.6	39
598	Wenxin Keli versus Sotalol for Paroxysmal Atrial Fibrillation Caused by Hyperthyroidism: A Prospective, Open Label, and Randomized Study. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-9.	0.5	9
599	Management of tachycardia. F1000prime Reports, 2015, 7, 60.	5.9	26
600	Overtreatment. Italian Journal of Medicine, 0, , .	0.2	0
601	Cardioversion in Non-Valvular Atrial Fibrillation. Deutsches Ärzteblatt International, 2015, 112, 856-62.	0.6	15
602	Comparisons of Hospitalization Rates Among Younger Atrial Fibrillation Patients Receiving Different Antiarrhythmic Drugs. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 292-300.	0.9	10
603	Arrhythmias in Dilated Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 221-233.	0.7	19

#	Article	IF	CITATIONS
604	Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. Expert Review of Cardiovascular Therapy, 2015, 13, 627-636.	0.6	4
605	Innovative Therapeutics for Atrial Fibrillation. Journal of Cardiovascular Pharmacology, 2015, 66, 409-411.	0.8	1
606	Detection of Abnormal Cardiac Activity Using Principal Component Analysis–-A Theoretical Study. IEEE Transactions on Biomedical Engineering, 2015, 62, 154-164.	2.5	9
607	New approaches to managing nonvalvular atrial fibrillation: what are the thromboembolic implications?. Journal of Thrombosis and Thrombolysis, 2015, 39, 345-352.	1.0	0
608	Five‥ear Outcomes of Catheter Ablation in Patients with Atrial Fibrillation and Left Ventricular Systolic Dysfunction. Journal of Cardiovascular Electrophysiology, 2015, 26, 363-370.	0.8	63
609	Atrial fibrillation: effects beyond the atrium?. Cardiovascular Research, 2015, 105, 238-247.	1.8	78
610	Improvement of the myocardial performance index in atrial fibrilation patients treated with amiodarone after cardioversion. Journal of Interventional Cardiac Electrophysiology, 2015, 42, 107-115.	0.6	6
611	Impact of Clinical Characteristics and Management on the Prognosis of Unselected Heart Failure Patients. Cardiovascular Drugs and Therapy, 2015, 29, 89-98.	1.3	17
612	Safety and efficacy of external electrical cardioversion in patients with left ventricular leads. Clinical Research in Cardiology, 2015, 104, 439-445.	1.5	5
613	Decade-long Trends in Atrial Fibrillation Incidence and Survival: A Community Study. American Journal of Medicine, 2015, 128, 260-267.e1.	0.6	83
614	Catheter Ablation for Atrial Fibrillation inÂHeart Failure Patients. JACC: Clinical Electrophysiology, 2015, 1, 200-209.	1.3	86
615	Atrial Fibrillation and Heart Failure: Update 2015. Progress in Cardiovascular Diseases, 2015, 58, 126-135.	1.6	50
616	Falling Cardiovascular Mortality in HeartÂFailure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	1.9	36
617	Autologous Dermal Fibroblast Injections Slow Atrioventricular Conduction and Ventricular Rate in Atrial Fibrillation in Swine. Circulation: Arrhythmia and Electrophysiology, 2015, 8, 439-446.	2.1	3
618	Ablation of Atrial Arrhythmias in Heart Failure. Heart Failure Clinics, 2015, 11, 305-317.	1.0	3
621	Heart Failure and Atrial Fibrillation: From Basic Science to Clinical Practice. International Journal of Molecular Sciences, 2015, 16, 3133-3147.	1.8	39
622	Real-World Observations with Dronedarone Compared to Other Anti-Arrhythmic Drugs in Recurrent Atrial Fibrillation. British Journal of Medicine and Medical Research, 2015, 5, 1088-1095.	0.2	1
623	Long-term oral anticoagulation for patients after successful catheter ablation of atrial fibrillation. Current Opinion in Cardiology, 2015, 30, 1-7.	0.8	15

#	Article	IF	Citations
624	What can rhythm control therapy contribute to prognosis in atrial fibrillation?. Heart, 2015, 101, 842-846.	1.2	9
626	Arrhythmia-Induced Cardiomyopathies. Journal of the American College of Cardiology, 2015, 66, 1714-1728.	1.2	277
627	Potassium Channel Blockade Enhances Atrial Fibrillation–Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade. Circulation, 2015, 132, 2203-2211.	1.6	41
628	Rate Control versus Rhythm Control in Atrial Fibrillation: Lessons Learned from Clinical Trials of Atrial Fibrillation. Progress in Cardiovascular Diseases, 2015, 58, 168-176.	1.6	8
629	Should β-Blockers Be Used in Patients With Heart Failure and Atrial Fibrillation?. Clinical Therapeutics, 2015, 37, 2215-2224.	1.1	43
630	Atrial fibrillation in heart failure: what should we do?. European Heart Journal, 2015, 36, ehv513.	1.0	243
631	Prognostic Significance of Resting Heart Rate and Use of Î ² -Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2015, 8, 871-879.	1.6	119
633	How to Improve Cardiac Resynchronization Therapy Benefit in Atrial Fibrillation Patients. Cardiac Electrophysiology Clinics, 2015, 7, 755-764.	0.7	3
634	Pulmonary Vein Isolation Compared to Rate Control in Patients with Atrial Fibrillation: A Systematic Review and Meta-analysis. Heart Lung and Circulation, 2015, 24, 744-752.	0.2	8
635	Ablation of atrial fibrillation. Trends in Cardiovascular Medicine, 2015, 25, 409-419.	2.3	10
636	Management of Atrial Fibrillation. Journal of Intensive Care Medicine, 2015, 30, 484-498.	1.3	5
637	Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation. Rational Pharmacotherapy in Cardiology, 2016, 12, 590-594.	0.3	0
638	British Society for Heart Failure: 18th Annual Meeting. British Journal of Cardiac Nursing, 2016, 11, 144-148.	0.0	1
639	Atrial Fibrillation Management in Older Heart Failure Patients: A Complex Clinical Problem. Heart International, 2016, 11, heartint.500023.	0.4	10
640	Evaluating the benefits of home-based management of atrial fibrillation: current perspectives. Journal of Pragmatic and Observational Research, 2016, Volume 7, 41-53.	1.1	0
641	ATRIAL FIBRILLATION: CURRENT PROBLEMS AND PROSPECTS OF MEDICAL CARE, TREATMENT AND PREVENTION. Rational Pharmacotherapy in Cardiology, 2016, 12, 196-203.	0.3	3
642	Effects of Renal Sympathetic Denervation in Comparison to \hat{I}^2 -Blocker on Heart Rate Control in Hypertensive Patients with Permanent Atrial Fibrillation. , 2016, 07, .		0
643	Pursuing early catheter ablation to treat atrial fibrillation in the congestive heart failure population: significance of the AATAC trial results. Journal of Thoracic Disease, 2016, 8, 1913-1915.	0.6	0

#	Article	IF	CITATIONS
644	Prediction of atrial fibrillation development and progression: Current perspectives. World Journal of Cardiology, 2016, 8, 267.	0.5	44
645	Recent Advances in the Pharmacological Management of Atrial Fibrillation. American Journal of Therapeutics, 2016, 23, e118-e138.	0.5	2
646	New Mechanism-based Approaches to Ablating Persistent AF. Journal of Cardiovascular Pharmacology, 2016, 67, 1-8.	0.8	0
647	Evaluating the Efficacy and Safety of Internal Cardioversion with Implantable Cardioverter Defibrillator Device for Atrial Fibrillation in Systolic Heart Failure Patients. Annals of Noninvasive Electrocardiology, 2016, 21, 181-188.	0.5	7
648	Long-term events following atrial fibrillation rate control or transcatheter ablation. Journal of Cardiovascular Medicine, 2016, 17, 187-193.	0.6	21
649	Effect of Late Gadolinium Enhancement on the Recovery of Left Ventricular Systolic Function After Pulmonary Vein Isolation. Journal of the American Heart Association, 2016, 5, .	1.6	25
651	Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ, The, 2016, 354, i4482.	3.0	528
654	Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device. Circulation, 2016, 133, 1637-1644.	1.6	630
655	Atrial Fibrillation in Heart Failure. Circulation, 2016, 133, 1631-1633.	1.6	3
656	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	1.0	13,008
659	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	12
660	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	0.6	754
661	Termination of atrial spiral waves by traction into peripheral non 1:1 conducting regions – A numerical study. Medical Engineering and Physics, 2016, 38, 1322-1329.	0.8	0
662	Biomarkers in Persistent AF and Heart Failure: Impact of Catheter Ablation Compared with Rate Control. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 926-934.	0.5	6
663	Reframing the association and significance of coâ€morbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	2.9	169
664	Outpatient Medications in Atrial Fibrillation. Contemporary Cardiology, 2016, , 195-217.	0.0	0
665	Rate Control in Atrial Fibrillation. Contemporary Cardiology, 2016, , 67-77.	0.0	0
666	Short Stay Management of Atrial Fibrillation. Contemporary Cardiology, 2016, , .	0.0	1

#	Article	IF	CITATIONS
667	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	2.9	5,272
668	Atrial Fibrillation as a Prognostic Indicator in Medium to Large‣ized Dogs with Myxomatous Mitral Valvular Degeneration and Congestive Heart Failure. Journal of Veterinary Internal Medicine, 2016, 30, 51-57.	0.6	36
669	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	1.0	5,689
670	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	0.7	3,523
671	Symptoms of Atrial Fibrillation. Contemporary Cardiology, 2016, , 51-59.	0.0	0
672	Rate control in atrial fibrillation. Lancet, The, 2016, 388, 818-828.	6.3	140
673	Rhythm control in atrial fibrillation. Lancet, The, 2016, 388, 829-840.	6.3	112
674	Characteristics and Outcomes of Concurrently Diagnosed New Rapid Atrial Fibrillation or Flutter and New Reduced Ejection Fraction. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1394-1403.	0.5	8
675	Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation – Shinken Database Analysis –. Circulation Journal, 2016, 80, 639-649.	0.7	45
676	Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation. Circulation, 2016, 134, 1068-1081.	1.6	70
677	Discontinuation of Dofetilide From QTÂProlongation and Ventricular Tachycardia inÂtheÂRealÂWorld. JACC: Clinical Electrophysiology, 2016, 2, 777-781.	1.3	14
678	How robust are clinical trials in heart failure?. European Heart Journal, 2017, 38, ehw427.	1.0	49
679	Distinguishing Tachycardia Mediated From Structural Cardiomyopathy: Association of Late Gadolinium Enhancement With Recovery of Ventricular Systolic Function Following Atrial FibrillationÂAblation. Journal of the American Heart Association, 2016, 5, .	1.6	0
680	The State of the Art. Mayo Clinic Proceedings, 2016, 91, 1778-1810.	1.4	154
681	Brain embolism. , 0, , 312-363.		1
682	The History of Surgery at the Montreal Heart Institute. Seminars in Thoracic and Cardiovascular Surgery, 2016, 28, 674-681.	0.4	0
683	A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. Clinical Medicine Insights: Cardiology, 2016, 10, CMC.S38444.	0.6	3
684	A Genetic Algorithm Optimization Method for Mapping Non-Conducting Atrial Regions: A Theoretical Feasibility Study. Cardiovascular Engineering and Technology, 2016, 7, 87-101.	0.7	2

#	Article	IF	CITATIONS
685	Patient-Centred Care of Older Adults With Cardiovascular Disease and Multiple Chronic Conditions. Canadian Journal of Cardiology, 2016, 32, 1097-1107.	0.8	25
686	Impact of genetic variants on the upstream efficacy of renin-angiotensin system inhibitors for the prevention of atrial fibrillation. American Heart Journal, 2016, 175, 9-17.	1.2	6
687	Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. Indian Heart Journal, 2016, 68, 663-670.	0.2	17
688	The importance of interactions between atrial fibrillation and heart failure. Clinical Medicine, 2016, 16, 272-276.	0.8	5
689	Catheter ablation for atrial fibrillation in congestive heart failure: consider the upside, consider the downside. Europace, 2016, 18, 1121-1122.	0.7	0
690	Temporal Patterns and Predictors of Rate vs Rhythm Control in Patients Attending a Multidisciplinary Atrial Fibrillation Clinic. Canadian Journal of Cardiology, 2016, 32, 1247.e7-1247.e13.	0.8	1
691	Rhythm Control Versus Rate Control andÂClinical Outcomes in Patients WithÂAtrial Fibrillation. JACC: Clinical Electrophysiology, 2016, 2, 221-229.	1.3	33
692	Management of Heart Failure. , 2016, , .		0
693	Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role. International Journal of Cardiology, 2016, 206, 71-76.	0.8	36
694	Comorbidity of atrial fibrillation and heart failure. Nature Reviews Cardiology, 2016, 13, 131-147.	6.1	152
695	Efficacy and safety of catheter ablation vs. rate control of atrial fibrillation in systolic left ventricular dysfunction. Herz, 2016, 41, 342-350.	0.4	9
696	Reducing Heart Failure Risks in Obese Patients. Current Cardiovascular Risk Reports, 2016, 10, 1.	0.8	1
697	Guidelines for Potassium Channel Blocker Use. Cardiac Electrophysiology Clinics, 2016, 8, 495-501.	0.7	1
698	Atrial Fibrillation and Heart Failure: Medical Management and Catheter Ablation. , 2016, , 207-218.		Ο
699	Deciphering the fundamental mechanisms of atrial fibrillation: a quest for over a century. Cardiovascular Research, 2016, 109, 465-466.	1.8	7
700	Catheter ablation of atrial fibrillation in patients with heart failure: impact of maintaining sinus rhythm on heart failure status and long-term rates of stroke and death. Europace, 2016, 18, 679-686.	0.7	61
701	Atrial Fibrillation, Heart Failure, and the Autonomic Nervous System. , 2016, , 25-41.		0
702	Rate Control Versus Rhythm Control inÂtheÂORBIT-AF Registry. JACC: Clinical Electrophysiology, 2016, 2, 230-232.	1.3	1

#	Article	IF	CITATIONS
703	Atrial fibrillation management: evaluating rate vs rhythm control. Expert Review of Cardiovascular Therapy, 2016, 14, 713-724.	0.6	3
705	Heart Failure With Preserved Ejection Fraction. Current Problems in Cardiology, 2016, 41, 145-188.	1.1	107
706	Rate Versus Rhythm Control for Atrial Fibrillation. Heart Failure Clinics, 2016, 12, 193-203.	1.0	2
707	Antiarrhythmic Drug Therapy for Atrial Fibrillation. Heart Failure Clinics, 2016, 12, 205-221.	1.0	21
708	Atrial Fibrillation Begets Heart Failure and Vice Versa. Circulation, 2016, 133, 484-492.	1.6	561
710	Clinical Pearls in Using Antiarrhythmic Drugs in the Outpatient Setting. Journal of Pharmacy Practice, 2016, 29, 77-86.	0.5	3
711	Heart rate and adverse outcomes in patients with atrial fibrillation: A combined AFFIRM and AF-CHF substudy. Heart Rhythm, 2016, 13, 54-61.	0.3	25
712	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. Progress in Cardiovascular Diseases, 2016, 58, 386-392.	1.6	6
713	Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIIA Registry. Revista Espanola De Cardiologia (English Ed), 2016, 69, 54-60.	0.4	12
714	Health-related quality of life changes in patients undergoing repeated catheter ablation for atrial fibrillation. Clinical Research in Cardiology, 2016, 105, 1-9.	1.5	11
715	Importance of non–pulmonary vein triggers ablation to achieve long-term freedom from paroxysmal atrial fibrillation in patients with low ejection fraction. Heart Rhythm, 2016, 13, 141-149.	0.3	106
716	Tratamiento antiarrÃŧmico actual de la fibrilación auricular no valvular en España. Datos del Registro FANTASIIA. Revista Espanola De Cardiologia, 2016, 69, 54-60.	0.6	20
717	Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function. Heart and Vessels, 2016, 31, 584-592.	0.5	15
718	Outcomes for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter Treated in Canadian Hospitals. Annals of Emergency Medicine, 2017, 69, 562-571.e2.	0.3	51
720	Short Stay Management of Acute Heart Failure. Contemporary Cardiology, 2017, , .	0.0	0
721	Focal Impulse and Rotor Modulation for the Treatment of Atrial Fibrillation: Locations and 1 Year Outcomes of Human Rotors Identified Using a 64â€Electrode Basket Catheter. Journal of Cardiovascular Electrophysiology, 2017, 28, 367-374.	0.8	26
724	Effect of Aggressive Blood Pressure Control on the Recurrence of Atrial Fibrillation After Catheter Ablation. Circulation, 2017, 135, 1788-1798.	1.6	66
725	The burden of proof: The current state of atrial fibrillation prevention and treatment trials. Heart Rhythm, 2017, 14, 763-782.	0.3	47

ARTICLE IF CITATIONS # Early Cardioversion in Atrial Fibrillation: Earlier Is Better, but Not Always and (Maybe) Not 726 2.0 1 Immediately. Current Atherosclerosis Reports, 2017, 19, 3. Electrocardiographic intervals associated with incident atrial fibrillation: Dissecting the QT 727 0.3 interval. Heart Rhythm, 2017, 14, 654-660. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of 728 0.3 1.671 atrial fibrillation. Heart Rhythm, 2017, 14, e275-e444. Arrhythmias and cardiomyopathy. Journal of Cardiovascular Medicine, 2017, 18, e145-e148. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet, The, 2017, 730 6.3 128 390, 1873-1887. Association of digitalis treatment with outcomes following myocardial infarction in patients with heart failure or evidence of left ventricular dysfunction: an analysis from the High-Risk Myocardial Infarction Database Initiative. Clinical Research in Cardiology, 2017, 106, 722-733. 1.5 Perioperative Outcomes and Safety of Atrial Fibrillation Catheter Ablation in Octogenarians: A 732 0.6 0 Retrospective Study and Review of the Benefits of Rhythm Control. Cardiology, 2017, 137, 173-178. How to Improve Cardiac Resynchronization Therapy Benefit in Atrial Fibrillation Patients. Heart 1.0 Failure Clinics, 2017, 13, 199-208. Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current 734 0.5 5 practice. Obstetric Medicine, 2017, 10, 74-78. Dyspnea in Paroxysmal Atrial Fibrillation: When Perception Falls Out of Rhythm With Reality. Journal of Cardiac Failure, 2017, 23, 563-565. Does heart rate really matter to patients with heart failure?. Current Opinion in Cardiology, 2017, 32, 736 4 0.8 209-216. Cardioverting acute atrial fibrillation and the risk of thromboembolism: not all patients are created 740 0.8 equal. Clinical Medicine, 2017, 17, 419-423. Antiarrhythmic Drug Management of Atrial Fibrillation. Cardiovascular Medicine, 2017, , 87-104. 741 0.0 0 Atrial fibrillation in heart failure with preserved ejection fraction: time to address the chicken <i>and</i> the egg. European Journal of Heart Failure, 2017, 19, 1698-1700. 742 Atrial Fibrillation in Heart Failure US Ambulatory Cardiology Practices and the Potential for Uptake of Catheter Ablation: An National Cardiovascular Data Registry (NCDR ®) Research to Practice (R2P) 743 1.6 8 Project. Journal of the American Heart Association, 2017, 6, . Catheter Ablation for Rate-Controlled Atrial Fibrillation. Journal of the American College of 744 Cardiology, 2017, 70, 1962-1963. Risk of Catheter Ablation for AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2017, 3, 1434-1436. 745 1.35 Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction. 747 1.2 Journal of the American College of Cardiology, 2017, 70, 1949-1961.

ARTICLE IF CITATIONS # 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of 748 0.8 503 Heart Failure. Canadian Journal of Cardiology, 2017, 33, 1342-1433. Long-term management of end-stage heart failure. Bailliere's Best Practice and Research in Clinical 1.7 Anaesthesiology, 2017, 31, 153-166. A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial. 752 0.8 37 BMJ Open, 2017, 7, e015099. Device Therapy for Rate Control: Pacing, Resynchronisation and AV Node Ablation. Heart Lung and Circulation, 2017, 26, 934-940. Impact of restrictive lung disorder on cardiovascular mortality in a general population: The Yamagata 754 0.8 18 (Takahata) study. International Journal of Cardiology, 2017, 241, 395-400. Should We Perform Catheter Ablation for Asymptomatic Atrial Fibrillation?. Circulation, 2017, 136, 1.6 490-499. Increasing Prevalence of Atrial Fibrillation and Permanent Atrial Arrhythmias in Congenital Heart 756 1.2 104 Disease. Journal of the American College of Cardiology, 2017, 70, 857-865. Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017. Heart Lung and Circulation, 2017, 26, 926-933. 0.2 Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. 758 1.2 114 Journal of the American College of Cardiology, 2017, 70, 2490-2500. Change Is Not Always Good. Journal of the American College of Cardiology, 2017, 70, 2501-2503. 1.2 A Knowledge-Modeling Approach to Integrate Multiple Clinical Practice Guidelines to Provide Evidence-Based Clinical Decision Support for Managing Comorbid Conditions. Journal of Medical 760 2.2 23 Systems, 2017, 41, 193. Atrial Fibrillation and Heart Failure â€" Cause or Effect?. Heart Lung and Circulation, 2017, 26, 967-974. 761 Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and 762 54 therapeutics., 2017, 176, 32-39. Catheter ablation versus rate control in patients with atrial fibrillation and heart failure. Medicine 0.4 (United States), 2017, 96, e9179. Newly developed atrial fibrillation progresses to a more severe <scp>INTERMACS</scp> score in a 764 patient with advanced heart failure due to dilated cardiomyopathy. Clinical Case Reports 0.2 2 (discontinued), 2017, 5, 2028-2033. Transcatheter Ablation of Atrial Fibrillation in Patients with Chronic Heart Failure., 0, , . Management of Arrhythmias in Heart Failure. Journal of Cardiovascular Development and Disease, 766 0.8 47 2017, 4, 3. Efficacy and effects on cardiac function of radiofrequency catheter ablation vs. direct current cardioversion of persistent atrial fibrillation with left ventricular systolic dysfunction. PLoS ONE, 1.1 2017, 12, e0174510.

#	Article	IF	CITATIONS
768	Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation – a prospective nationwide cohort. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2017, 25, 81.	1.1	5
769	A Five Year Audit of DC Cardioversion for Patients with Atrial Fibrillation in East London. Journal of Universal Surgery, 2017, 04, .	0.1	0
770	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. Korean Circulation Journal, 2017, 47, 555.	0.7	56
771	Novel Scoring System for Distinction Between Paroxysmal and Non-Paroxysmal Atrial Fibrillation. Circulation Journal, 2017, 81, 788-793.	0.7	2
772	Atrial tachyarrhythmia in adult congenital heart disease. World Journal of Cardiology, 2017, 9, 496.	0.5	16
774	Pharmacologic Rhythm Control versus Rate Control in Heart Failure and Atrial Fibrillation. Journal Kedokteran Indonesia, 2017, 4, .	0.0	0
775	Atrial fibrillation in heart failure — time to revise the guidelines?. Nature Reviews Cardiology, 2018, 15, 199-200.	6.1	0
776	Translational Challenges in Atrial Fibrillation. Circulation Research, 2018, 122, 752-773.	2.0	131
777	Stroke and Cardiovascular Events After Ablation or Antiarrhythmic Drugs for Treatment of Patients With Atrial Fibrillation. American Journal of Cardiology, 2018, 121, 1192-1199.	0.7	34
778	Impact of Evolving Comorbidities on Outcomes After Catheter Ablation of Atrial Fibrillation in the United States Between 2003 and 2013. JACC: Clinical Electrophysiology, 2018, 4, 704-706.	1.3	3
779	Atrial Fibrillation in Patients with Heart Failure: Current State and Future Directions. American Journal of Cardiovascular Drugs, 2018, 18, 347-360.	1.0	6
781	Catheter ablation of atrial fibrillation in heart failure with reduced ejection fraction. Journal of Cardiovascular Electrophysiology, 2018, 29, 1049-1058.	0.8	11
782	Emergency medicine considerations in atrial fibrillation. American Journal of Emergency Medicine, 2018, 36, 1070-1078.	0.7	16
783	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, e1-e160.	0.7	767
784	It is time for catheter ablation to be considered a first-line treatment option in patients with atrial fibrillation and heart failure. Heart Rhythm, 2018, 15, 658-659.	0.3	6
785	Reply. Journal of Critical Care, 2018, 45, 247-248.	1.0	1
786	Paradigm Shift for Treatment of Atrial Fibrillation in Heart Failure. New England Journal of Medicine, 2018, 378, 468-469.	13.9	9
787	Catheter Ablation for Atrial Fibrillation with Heart Failure. New England Journal of Medicine, 2018, 378, 417-427.	13.9	1,611

#	Article	IF	CITATIONS
788	Atrial Fibrillation Ablation and its Impact on Stroke. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 2.	0.4	5
789	Heart failure and atrial fibrillation: Can we break this nexus?. International Journal of Cardiology, 2018, 252, 142-143.	0.8	3
790	The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: Insights from the, United Kingdom ACALM registry. International Journal of Cardiology, 2018, 252, 117-121.	0.8	33
791	Clinical Trials for Atrial Fibrillation—What Do We Know?. , 2018, , 630-642.		0
792	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58.	1.2	9
793	Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace, 2018, 20, 1442-1450.	0.7	47
794	Treatment Strategies for Atrial Fibrillation With Left Ventricular Systolic Dysfunction ― Meta-Analysis ―. Circulation Journal, 2018, 82, 1770-1777.	0.7	9
795	Atrial Fibrillation, an Under-Appreciated Reversible Cause of Cardiomyopathy: Implications for Clinical Practice From the CAMERA-MRI Study. Heart Lung and Circulation, 2018, 27, 652-655.	0.2	3
796	How to manage various arrhythmias and sudden cardiac death in the cardiovascular intensive care. Journal of Intensive Care, 2018, 6, 23.	1.3	9
797	Cardiomyopathies rythmiques. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2018, 2018, 2-9.	0.0	Ο
798	Left Atrial Reverse Remodeling After Catheter Ablation of Nonparoxysmal Atrial Fibrillation in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2018, 122, 89-96.	0.7	22
799	Impact of catheter ablation of atrial fibrillation on long-term clinical outcomes in patients with heart failure. Journal of Cardiology, 2018, 72, 240-246.	0.8	40
800	Elevated Circulating Fibrocytes Is a Marker of Left Atrial Fibrosis and Recurrence of Persistent Atrial Fibrillation. Journal of the American Heart Association, 2018, 7, .	1.6	28
801	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. Drugs and Aging, 2018, 35, 365-373.	1.3	17
802	Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. American Heart Journal, 2018, 199, 192-199.	1.2	107
803	Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation. Current Problems in Cardiology, 2018, 43, 241-283.	1.1	14
804	Atrial Fibrillation: A Riddle Wrapped in a Mystery Inside an Enigma. Revista Espanola De Cardiologia (English Ed), 2018, 71, 139-140.	0.4	1
805	Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure. Heart Failure Reviews, 2018, 23, 27-36.	1.7	40

#	Article	IF	CITATIONS
806	Acute Management of Atrial Fibrillation. Cardiology Clinics, 2018, 36, 141-159.	0.9	11
807	Rotors in Human Atrial Fibrillation. , 2018, , 426-436.		1
809	Fibrilación auricular: un acertijo envuelto en un misterio dentro de un enigma. Revista Espanola De Cardiologia, 2018, 71, 139-140.	0.6	1
810	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. Leukemia and Lymphoma, 2018, 59, 1554-1564.	0.6	43
811	Trends in outpatient antiâ€arrhythmic prescriptions for atrial fibrillation and left atrial ablation in Australia: 1997–2016. Internal Medicine Journal, 2018, 48, 427-432.	0.5	6
812	Biatrial Electrical and Structural AtrialÂChanges in Heart Failure. JACC: Clinical Electrophysiology, 2018, 4, 87-96.	1.3	18
813	Diagnosis and Treatment of Heart Failure for Inpatient Providers. , 2018, , 3-21.		2
814	Ablation for Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2018, 4, 1.	1.2	19
815	Tactics of Antiarrhythmic Therapy in Comorbid Elderly and Senile Patients with Paroxysmal and Recurrent Atrial Fibrillation. Rational Pharmacotherapy in Cardiology, 2018, 14, 670-677.	0.3	2
816	Who benefit most from catheter ablation of persistent atrial fibrillation?. Journal of Thoracic Disease, 2018, 10, 614-616.	0.6	0
817	Dose-independent influence of metoprolol on cardiac and motor functions, QoL, and mental status in Chinese patients with CHF. Therapeutics and Clinical Risk Management, 2018, Volume 15, 23-31.	0.9	2
818	2018 Korean Guideline of Atrial Fibrillation Management. Korean Circulation Journal, 2018, 48, 1033.	0.7	108
819	Atrial Fibrillation and Left Ventricle Dysfunction Relationship (New Concept). Journal of Cardiovascular Diseases & Diagnosis, 2018, s2, .	0.0	1
820	Cardiac Dysrhythmias. Advances in Anesthesia, 2018, 36, 181-199.	0.5	4
821	Treatment of Atrial Fibrillation in Patients with Co-existing Heart Failure and Reduced Ejection Fraction: Time to Revisit the Management Guidelines?. Arrhythmia and Electrophysiology Review, 2018, 7, 91.	1.3	12
822	2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2018, 34, 1371-1392.	0.8	195
823	Rhythm-control vs rate-control in the elderly: When to do it and which drug to prefer?. Monaldi Archives for Chest Disease, 2018, 88, 949.	0.3	0
824	A bridge to the future: Maintenance of sinus rhythm in patients with atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1604-1606.	0.8	0

#	Article	lF	Citations
825	Metaâ€analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction. Clinical Cardiology, 2018, 41, 1430-1438.	0.7	18
826	Cardioversion for atrial fibrillation – how to prevent thromboembolic complications?. Annals of Medicine, 2018, 50, 549-555.	1.5	12
827	Catheter ablation of atrial fibrillation and outcomes in heart failure patients: seeking the treasure in the CASTLE. Cardiovascular Research, 2018, 114, e50-e52.	1.8	1
828	Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry. Heart and Vessels, 2018, 33, 1534-1546.	O.5	6
829	Huff and Puff, This CASTLE Is Made of Bricks. Circulation, 2018, 138, 754-755.	1.6	2
830	Catheter ablation of atrial fibrillation with heart failure: An updated meta-analysis of randomized trials. International Journal of Cardiology, 2018, 269, 170-173.	0.8	23
831	Arrhythmia-Induced Cardiomyopathy. Deutsches Ärzteblatt International, 2018, 115, 335-341.	0.6	27
832	Incidence of thromboembolic events following atrial fibrillation catheter ablation and rate control strategies according to the kind of oral anticoagulation: A systematic review and meta-analysis. International Journal of Cardiology, 2018, 270, 172-179.	0.8	1
833	CT in the Management of Cardiac Arrhythmias. , 2018, , 271-301.		0
834	Mechanisms and Clinical Significance of Arrhythmia-Induced Cardiomyopathy. Canadian Journal of Cardiology, 2018, 34, 1449-1460.	0.8	30
835	National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung and Circulation, 2018, 27, 1209-1266.	0.2	216
836	Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study. Frontiers in Pharmacology, 2018, 9, 448.	1.6	5
837	Multifractal Desynchronization of the Cardiac Excitable Cell Network During Atrial Fibrillation. I. Multifractal Analysis of Clinical Data. Frontiers in Physiology, 2018, 8, 1139.	1.3	3
838	Longâ€ŧerm risk of stroke and bleeding post–atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 2018, 29, 1355-1362.	0.8	15
839	The Timing and Role of Atrial Fibrillation Ablation in Heart Failure Patients. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	2
840	Atrial fibrillation in aging population. Aging Medicine (Milton (N S W)), 2018, 1, 67-74.	0.9	11
841	Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Journal of Interventional Cardiac Electrophysiology, 2018, 53, 19-29.	0.6	34
842	National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart Lung and Circulation, 2018, 27, 1123-1208.	0.2	262

ARTICLE IF CITATIONS Cardiac Arrhythmia in Heart Failure. , 2018, , 394-410. 843 0 The Clinical Benefits and Mortality Reduction Associated With CatheterÂAblation in Subjects With 844 1.3 AtrialÂFibrillation. JACC: Clinical Électrophysiology, 2018, 4, 626-635. Minimally Invasive Delivery of Hydrogel-Encapsulated Amiodarone to the Epicardium Reduces Atrial 845 2.1 17 Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006408. Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis 846 24 of randomized controlled trials. BMC Cardiovascular Disorders, 2018, 18, 165. Atrial Fibrillation and Heart Failure: Untangling a Modern Gordian Knot. Canadian Journal of 847 0.8 23 Cardiology, 2018, 34, 1437-1448. 848 Electrical manipulation of the failing heart. Heart Failure Reviews, 2018, 23, 885-896. 1.7 Catheter ablation for atrial fibrillation: current patient selection and outcomes. Expert Review of 849 0.6 8 Cardiovascular Therapy, 2018, 16, 679-692. A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clinical Cardiology, 2018, 41, 862-870. Meta-Analysis Comparing Catheter-Guided Ablation Versus Conventional Medical Therapy for Patients 851 With Atrial Fibrillation and Heart Failure With Reduced Ejection Fraction. American Journal of 25 0.7 Cardiology, 2018, 122, 806-813. Association of catheter ablation for atrial fibrillation with mortality and stroke: A systematic review 0.8 and meta-analysis. International Journal of Cardiology, 2018, 266, 136-142. New-onset atrial fibrillation in critically ill patients – Implications for rhythm rather than rate 853 0.8 5 control therapy?. International Journal of Cardiology, 2018, 266, 147-148. Atrial fibrillation and heart failure with preserved ejection fraction: Insights on a unique clinical phenotype from a nationally-representative United States cohort. International Journal of Cardiology, 2018, 266, 112-118. 0.8 30 Risks of Intensive Treatment of Long-Standing Atrial Fibrillation in Patients With Chronic Heart 855 Failure With a Reduced or Preserved Ejection Fraction. Circulation: Cardiovascular Quality and 0.9 1 Outcomes, 2019, 12, e005747. Atrial Tachyarrhythmias Among Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2019, 5, 459-466. 1.3 Heart Failure Differentially Modulates Natural (Sinoatrial Node) and Ectopic (Pulmonary Veins) Pacemakers: Mechanism and Therapeutic Implication for Atrial Fibrillation. International Journal of 857 1.8 8 Molecular Sciences, 2019, 20, 3224. Atrial Remodeling Following Catheter Ablation for Atrial Fibrillation-MediatedÂCardiomyopathy. JACC: 30 Clinical Electrophysiology, 2019, 5, 681-688. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart 859 Failure and Preserved Ejection Fraction. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 1.0 3 405-411. Risk of Newâ€Onset Atrial Fibrillation Among Asian Chronic Hepatitis C Virus Carriers: A Nationwide 1.6 Populationâ€Based Cohort Study. Journal of the American Heart Association, 2019, 8, e012914.

#	Article	IF	CITATIONS
862	A review of the epidemiology of atrial fibrillation in sub‣aharan Africa. Journal of Cardiovascular Electrophysiology, 2019, 30, 3006-3016.	0.8	17
863	KSHF Guidelines for the Management of Acute Heart Failure: Part III. Specific Management of Acute Heart Failure According to the Etiology and Co-morbidity. Korean Circulation Journal, 2019, 49, 46.	0.7	12
864	Internal Versus External Electrical Cardioversion of Atrial Arrhythmia in Patients With Implantable Cardioverter-Defibrillator. Circulation, 2019, 140, 1061-1069.	1.6	11
865	Is an elevated burden of antiarrhythmic drug (AAD) side-effects the unavoidable price to be traded for a durable suppression of AF relapses in ablated patients? The weaknesses and risks of the AAD suppression algorithm used by current models of AF secondary prevention after catheter ablation. European Journal of Clinical Pharmacology, 2019, 75, 873-874.	0.8	0
866	Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2019, 19, 18.	0.7	47
867	ACC/AHA Versus ESC Guidelines onÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 73, 2756-2768.	1.2	195
868	HeartÂFailure and Atrial Fibrillation, LikeÂFireÂandÂFury. JACC: Heart Failure, 2019, 7, 447-456.	1.9	178
869	Prognostic Impact of Atrial Fibrillation in Acute Myocardial Infarction and Cardiogenic Shock. Circulation: Cardiovascular Interventions, 2019, 12, e007661.	1.4	18
870	Atrial Fibrillation in Heart Failure—Diagnostic, Therapeutic, and Prognostic Relevance. Current Heart Failure Reports, 2019, 16, 108-115.	1.3	2
871	β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation—a meta-analysis. BMC Cardiovascular Disorders, 2019, 19, 135.	0.7	5
872	Incidence and complications of perioperative atrial fibrillation after non-cardiac surgery for malignancy. PLoS ONE, 2019, 14, e0216239.	1.1	26
874	Arrhythmia-Induced Cardiomyopathy. Journal of the American College of Cardiology, 2019, 73, 2328-2344.	1.2	195
875	Invasive therapies for patients with concomitant heart failure and atrial fibrillation. Heart Failure Reviews, 2019, 24, 821-829.	1.7	2
876	Is rhythm control superior to rate control in patients with heart failure and preserved ejection fraction?. Journal of Cardiology, 2019, 74, 233-234.	0.8	0
877	Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure. Cardiovascular Therapeutics, 2019, 2019, 1-10.	1.1	10
878	Consider temporal aggressive rhythm control before ICD implantation in patients with heart failure with reduced ejection fraction. Europace, 2019, 21, 835-837.	0.7	0
879	Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 325-331.	0.6	7
880	Mechanisms of Improved Mortality Following Ablation. Cardiology Clinics, 2019, 37, 177-183.	0.9	2

#	Article	IF	CITATIONS
881	Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation. European Journal of Heart Failure, 2019, 21, 398-401.	2.9	0
882	Relationships between maintenance of sinus rhythm and clinical outcomes in patients with heart failure with preserved ejection fraction and atrial fibrillation. Journal of Cardiology, 2019, 74, 235-244.	0.8	34
883	Left atrial ablation for management of atrial fibrillation: CABANA vs. real-world data. Apples and oranges?. European Heart Journal, 2019, 40, 1265-1267.	1.0	5
884	Does Left Ventricular Systolic Function Matter? Treating Atrial Fibrillation in HFrEF Versus HFpEF. Cardiology Clinics, 2019, 37, 157-166.	0.9	1
885	Imaging for Risk Stratification in Atrial Fibrillation with Heart Failure. Cardiology Clinics, 2019, 37, 147-156.	0.9	0
886	Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure. Cardiology Clinics, 2019, 37, 139-146.	0.9	3
887	Management of Atrial Fibrillation in Patients with Heart Failure: Time to Implement Ablation Control. Current Cardiology Reports, 2019, 21, 10.	1.3	2
888	Atrial Fibrillation Ablation Should Be First-line Therapy in Patients with Heart Failure Reduced Ejection Fraction. Cardiology Clinics, 2019, 37, 185-195.	0.9	0
889	Rapid improvement in left ventricular function after sinus rhythm restoration in patients with idiopathic cardiomyopathy and atrial fibrillation. Europace, 2019, 21, 871-878.	0.7	15
890	Current Pathophysiological and Genetic Aspects of Dilated Cardiomyopathy. , 2019, , .		0
891	Implication of Preoperative Existence of Atrial Fibrillation on Hemocompatibility-Related Adverse Events During Left Ventricular Assist Device Support. Circulation Journal, 2019, 83, 1286-1292.	0.7	8
892	Modelling the lifetime cost-effectiveness of catheter ablation for atrial fibrillation with heart failure. BMJ Open, 2019, 9, e031033.	0.8	18
893	Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. European Heart Journal, 2019, 40, 3793-3799c.	1.0	60
894	Influence of heart rate control on exercise capacity and quality of life in patients with permanent atrial fibrillation. BMC Cardiovascular Disorders, 2019, 19, 308.	0.7	4
895	Pitfall in the anticoagulant therapy in patients with paroxysmal atrial fibrillation and heart failure. Journal of the Chinese Medical Association, 2019, 82, 743-744.	0.6	0
896	Atrial Fibrillation–Mediated Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007809.	2.1	26
897	Managements and outcomes of hospitalized heart failure patients with paroxysmal vs nonparoxysmal atrial fibrillation in Taiwan. Journal of the Chinese Medical Association, 2019, 82, 356-362.	0.6	1
898	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines—Heart Failure. Journal of the American Heart Association, 2019, 8, e011560.	1.6	68

#	Article	IF	CITATIONS
899	Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions. Heart Failure Reviews, 2019, 24, 41-54.	1.7	59
900	The impact of catheter ablation for atrial fibrillation in heart failure. Journal of Arrhythmia, 2019, 35, 33-42.	0.5	8
901	Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry. Clinical Research in Cardiology, 2019, 108, 395-401.	1.5	15
902	Singleâ€center experience of the FIRM technique to ablate paroxysmal and persistent atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2019, 30, 493-502.	0.8	5
903	Atrial fibrillation ablation in heart failure. European Heart Journal, 2019, 40, 663-671.	1.0	38
904	Potential use of ivabradine for treatment of atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2019, 30, 253-254.	0.8	1
905	Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion. Annals of Noninvasive Electrocardiology, 2019, 24, e12616.	0.5	8
906	Clarity and controversy around rate control in AF, the orphan child in AF therapeutics. International Journal of Cardiology, 2019, 287, 189-194.	0.8	1
907	Atrial Fibrillation and Heart Failure in Women. Heart Failure Clinics, 2019, 15, 55-64.	1.0	19
908	Catheter ablation of atrial fibrillation—A key role in heart failure therapy?. Clinical Cardiology, 2019, 42, 400-405.	0.7	8
909	15-Year Trends in Patients Hospitalised With Heart Failure and Enrolled in an Australian Heart Failure Management Program. Heart Lung and Circulation, 2019, 28, 1646-1654.	0.2	11
910	History of Atrial Fibrillation and Trajectory of Decongestion in AcuteÂHeart Failure. JACC: Heart Failure, 2019, 7, 47-55.	1.9	10
911	Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons. Europace, 2019, 21, 445-450.	0.7	7
912	Common Atrial and Ventricular Arrhythmias. Contemporary Cardiology, 2019, , 419-447.	0.0	0
913	Catheter Ablation Versus Medical Therapy for Atrial Fibrillation in Patients With Heart Failure: A Meta-Analysis of Randomised Controlled Trials. Heart Lung and Circulation, 2019, 28, 707-718.	0.2	24
914	Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation. PharmacoEconomics - Open, 2019, 3, 119-126.	0.9	1
915	Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions. European Heart Journal, 2020, 41, 1764-1774.	1.0	11
916	A Compelling Case for Less Aggressive Arrhythmia Management in Patients With Chronic Heart Failure and Long-Standing Atrial Fibrillation. Journal of Cardiac Failure, 2020, 26, 85-92.	0.7	3

#	Article	IF	CITATIONS
917	With our powers combined: Does the pooled analysis of existing randomized data regarding treatment of atrial fibrillation in heart failure settle the case for catheter ablation?. European Heart Journal, 2020, 41, 2874-2877.	1.0	2
918	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	1.2	3
919	Management of Arrhythmias and Device Therapy in Heart Failure. , 2020, , 549-567.		0
920	Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. European Heart Journal, 2020, 41, 2863-2873.	1.0	84
921	Current challenges in sudden cardiac death prevention. Heart Failure Reviews, 2020, 25, 99-106.	1.7	7
922	Long-term experience of atrioventricular node ablation in patients with refractory atrial arrhythmias. Heart and Vessels, 2020, 35, 699-704.	0.5	0
923	Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial. American Heart Journal, 2020, 220, 1-11.	1.2	12
924	Safety and efficacy of catheter ablation in atrial fibrillation patients with left ventricular dysfunction. Clinical Cardiology, 2020, 43, 305-314.	0.7	8
925	Clinical Outcomes of Rate vs Rhythm Control for Atrial Fibrillation in Older People: A Systematic Review and Meta-Analysis. Drugs and Aging, 2020, 37, 19-26.	1.3	13
926	The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacological Research, 2020, 151, 104521.	3.1	50
927	Determinants of sinus rhythm maintenance in patients with early-persistent atrial fibrillation and heart failure. Clinical Research in Cardiology, 2020, 109, 787-789.	1.5	3
928	Trends in Antiarrhythmic Drug Use in Denmark Over 19 Years. American Journal of Cardiology, 2020, 125, 562-569.	0.7	6
929	Comparative Therapeutic Assessment of Atrial Fibrillation in Heart Failure With Reduced Ejection Fraction—A Network Meta-Analysis. American Journal of Therapeutics, 2020, 27, e286-e296.	0.5	3
930	Surgical ablation of atrial fibrillation in patients with heart failure. Journal of Thoracic and Cardiovascular Surgery, 2020, 162, 1100-1105.	0.4	6
931	Addressing Comorbidities in Heart Failure. Heart Failure Clinics, 2020, 16, 441-456.	1.0	13
932	Strategies for Rhythm Control in Atrial Fibrillation. Indian Journal of Clinical Cardiology, 2020, 1, 94-107.	0.3	1
933	Ablación de venas pulmonares: estrategia prometedora para la fibrilación auricular en pacientes con insuficiencia cardÃaca. Medicina ClÃnica, 2020, 155, 445-447.	0.3	0
934	Mutual relationship between heart failure and atrial fibrillation. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	2

#	Article	IF	CITATIONS
935	Catheter ablation and mortality, stroke and heart failure readmission with atrial fibrillation. Open Heart, 2020, 7, e001369.	0.9	3
936	Thirtyâ€day readmissions after atrial fibrillation catheter ablation in patients with heart failure. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 930-940.	0.5	4
937	Randomized Trials Versus CommonÂSense and Clinical Observation. Journal of the American College of Cardiology, 2020, 76, 580-589.	1.2	50
938	The Canadian Cardiovascular Society Atrial Fibrillation Guidelines Program: A Look Back Over the Last 10 Years and a Look Forward. Canadian Journal of Cardiology, 2020, 36, 1839-1842.	0.8	6
939	The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Canadian Journal of Cardiology, 2020, 36, 1847-1948.	0.8	313
940	Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e016309.	1.6	23
941	Pharmacological rhythm versus rate control in patients with atrial fibrillation and heart failure: the CASTLE-AF trial. Journal of Interventional Cardiac Electrophysiology, 2021, 61, 609-615.	0.6	15
942	Left atrial fibrosis predicts left ventricular ejection fraction response after atrial fibrillation ablation in heart failure patients: the Fibrosis-HF Study. Europace, 2020, 22, 1812-1821.	0.7	13
943	Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. New England Journal of Medicine, 2020, 383, 1305-1316.	13.9	1,071
944	Atrioventricular junctional ablation: The good, the bad, the better. Heart Rhythm O2, 2020, 1, 311-314.	0.6	5
945	Pulmonary vein isolation: A promising strategy for the treatment of atrial fibrillation in patients with heart failure. Medicina ClÃnica (English Edition), 2020, 155, 445-447.	0.1	0
946	Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction. JACC: Clinical Electrophysiology, 2020, 6, 1721-1731.	1.3	20
947	Atrial Fibrillation Management in Heart Failure: Interrupting the Vicious Cycle. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.4	0
948			
	The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358.	1.7	15
949	The management of atrial fibrillation in heart failure: an expert panel consensus. Heart Failure Reviews, 2020, 26, 1345-1358. Atrial fibrillation ablation in heart failure. European Heart Journal Supplements, 2020, 22, E50-E53.	1.7 0.0	15 7
	Reviews, 2020, 26, 1345-1358. Atrial fibrillation ablation in heart failure. European Heart Journal Supplements, 2020, 22, E50-E53. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace,		
949	Reviews, 2020, 26, 1345-1358. Atrial fibrillation ablation in heart failure. European Heart Journal Supplements, 2020, 22, E50-E53. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in	0.0	7

#	Article	IF	CITATIONS
953	Prognostic significance of resting heart rate in atrial fibrillation patients with heart failure with reduced ejection fraction. Heart and Vessels, 2020, 35, 1109-1115.	0.5	7
954	Atrial arrhythmias in chronic lung diseaseâ€associated pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-13.	0.8	10
955	Early versus delayed cardioversion: why should we wait?. Expert Review of Cardiovascular Therapy, 2020, 18, 149-154.	0.6	2
956	Population-Level Sex Differences and Predictors for Treatment With Catheter Ablation in Patients With Atrial Fibrillation and Heart Failure. CJC Open, 2020, 2, 85-93.	0.7	3
957	Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm, 2020, 17, 1057-1065.	0.3	54
958	Outcomes of incident atrial fibrillation in heart failure with preserved or reduced ejection fraction: A communityâ€based study. Journal of Cardiovascular Electrophysiology, 2020, 31, 2275-2283.	0.8	7
959	Rhythm Control of Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2020, 22, 83.	1.3	3
960	Association Between Atrial Fibrillation and Sudden Cardiac Death. Circulation Research, 2020, 127, 301-309.	2.0	39
961	Atrial fibrillation surgery with a focus on patients with reduced left ventricular function and heart failure. Europace, 2020, 22, 517-521.	0.7	1
962	Effectiveness of catheter ablation of atrial fibrillation according to heart failure etiology. Journal of Arrhythmia, 2020, 36, 84-92.	0.5	7
963	Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions. Expert Review of Cardiovascular Therapy, 2020, 18, 85-101.	0.6	2
964	Rhythm versus rate control strategies regarding anticoagulant use in elderly non-valvular atrial fibrillation patients: Subanalysis of the ANAFIE (All Nippon AF In the Elderly) Registry. Journal of Cardiology, 2020, 76, 87-93.	0.8	6
965	CARDIOPATÃA EN EL PACIENTE ANCIANO. Revista Médica ClÃnica Las Condes, 2020, 31, 21-27.	0.2	0
966	Current pharmacotherapeutic strategies for cardiac arrhythmias in heart failure. Expert Opinion on Pharmacotherapy, 2020, 21, 339-352.	0.9	4
967	Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure. Europace, 2020, 22, 739-747.	0.7	10
968	Digoxin, mortality, and cardiac hospitalizations in patients with atrial fibrillation and heart failure with reduced ejection fraction and atrial fibrillation: An AF-CHF analysis. International Journal of Cardiology, 2020, 313, 48-54.	0.8	12
969	Atrial arrhythmias in heart failure with a reduced ejection fraction. Current Opinion in Cardiology, 2020, 35, 271-275.	0.8	0
970	Improving exercise capacity and quality of life using nonâ€invasive heart failure treatments: evidence from clinical trials. European Journal of Heart Failure, 2021, 23, 92-113.	2.9	67

#	Article	IF	CITATIONS
971	Heart Failure With Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 1839-1859.	0.6	30
972	Atrial fibrillation ablation in heart failure: What do we know? What can we do?. Europace, 2021, 23, 353-361.	0.7	5
973	Atrial fibrillation in dilated cardiomyopathy: Outcome prediction from an observational registry. International Journal of Cardiology, 2021, 323, 140-147.	0.8	26
974	Obesity Paradox and 12ÂMonth Outcome in Patients with Atrial Fibrillation. Archives of Medical Research, 2021, 52, 233-239.	1.5	7
975	Chronic Amiodarone Use and the Risk of Cancer: A Systematic Review and Meta-analysis. CJC Open, 2021, 3, 109-114.	0.7	4
976	Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy. European Journal of Arrhythmia & Electrophysiology, 2021, 7, 19.	0.2	0
977	Is Atrial Fibrillation Ablation Really Beneficial in Patients with Heart Failure?. International Journal of Heart Failure, 2021, 3, 197.	0.9	0
978	A Comparison of Rate Control Agents for the Treatment of Atrial Fibrillation: Follow-Up Investigation of the AFFIRM Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 328-334.	1.0	5
979	World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update. Global Heart, 2021, 16, 41.	0.9	39
980	The crosstalk between cardiomyocyte calcium and inflammasome signaling pathways in atrial fibrillation. Pflugers Archiv European Journal of Physiology, 2021, 473, 389-405.	1.3	18
981	Symptom management strategies: Rhythm vs rate control in patients with atrial fibrillation in the Balkan region: Data from the BALKANâ€AF survey. International Journal of Clinical Practice, 2021, 75, e14080.	0.8	3
982	Fibrilação Atrial (Parte 2) – Ablação por Cateter. Arquivos Brasileiros De Cardiologia, 2021, 116, 334-345.	0.3	0
983	Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: results of the multicenter RIF-CHF register. Russian Journal of Cardiology, 2021, 26, 4200.	0.4	7
984	Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine, 2021, 10, 1341.	1.0	2
985	The Benefit of Atrioventricular Junction Ablation for Permanent Atrial Fibrillation and Heart Failure Patients Receiving Cardiac Resynchronization Therapy: An Updated Systematic Review and Meta-analysis. Indian Pacing and Electrophysiology Journal, 2021, 21, 101-111.	0.3	10
986	Can the Past Re-Shape the Future?. JACC: Clinical Electrophysiology, 2021, 7, 391-394.	1.3	0
987	Machine Learning Methodologies for Prediction of Rhythm-Control Strategy in Patients Diagnosed With Atrial Fibrillation: Observational, Retrospective, Case-Control Study. JMIR Medical Informatics, 2021, 9, e29225.	1.3	5
988	Atrial Fibrillation and Heart Failure. Cardiac Electrophysiology Clinics, 2021, 13, 47-62.	0.7	19

#	Article	IF	CITATIONS
989	The RACE to the EAST. In pursuit of rhythm control therapy for atrial fibrillation—a dedication to Harry Crijns. Europace, 2021, 23, ii34-ii39.	0.7	3
990	Early atrial fibrillation detection and the transition to comprehensive management. Europace, 2021, 23, ii46-ii51.	0.7	19
991	Catheter Ablation of Atrial Fibrillation in Heart Failure: from Evidences to Guidelines. Current Heart Failure Reports, 2021, 18, 153-162.	1.3	0
992	Sex-Specific Prevalence, Incidence, andÂMortality Associated With AtrialÂFibrillation in HeartÂFailure. JACC: Clinical Electrophysiology, 2021, 7, 1366-1375.	1.3	10
993	Implantation of a cardiac contractility modulator in chronic heart failure and atrial fibrillation: results of a 6-month follow-up of one hundred patients. Vestnik Transplantologii I Iskusstvennykh Organov, 2021, 23, 30-37.	0.1	2
994	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. American Heart Journal, 2021, 234, 90-100.	1.2	20
995	Genetics of atrial fibrillation—practical applications for clinical management: if not now, when and how?. Cardiovascular Research, 2021, 117, 1718-1731.	1.8	11
996	The role of atrial fibrillation catheter ablation in patients with heart failure. Progress in Cardiovascular Diseases, 2021, 66, 80-85.	1.6	1
997	Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ, The, 2021, 373, n991.	3.0	64
998	Drastic Cardiac Reverse Remodeling Following Catheter Ablation in Patients with Atrial Fibrillation and Heart Failure. Medicina (Lithuania), 2021, 57, 511.	0.8	1
999	Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. Heart Rhythm, 2021, 18, 709-716.	0.3	24
1000	JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2021, 85, 1104-1244.	0.7	77
1001	Impact of catheter ablation for atrial fibrillation in patients with heart failure and left ventricular systolic dysfunction. Revista Portuguesa De Cardiologia, 2021, 40, 437-444.	0.2	5
1003	Left ventricular improvement after catheter ablation of atrial fibrillation: What ablation procedure and for whom?. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 445-446.	0.2	0
1004	Impact of catheter ablation for atrial fibrillation in patients with heart failure and left ventricular systolic dysfunction. Revista Portuguesa De Cardiologia (English Edition), 2021, 40, 437-444.	0.2	2
1005	Circulating Soluble Suppression of Tumorigenicity 2 Predicts Recurrence After Radiofrequency Ablation of Persistent Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2021, 8, 653312.	1.1	4
1006	Update on management of atrial fibrillation in heart failure: a focus on ablation. Heart, 2022, 108, 422-428.	1.2	22
1007	Left ventricular improvement after catheter ablation of atrial fibrillation: What ablation procedure and for whom?. Revista Portuguesa De Cardiologia, 2021, 40, 445-446.	0.2	Ο

#	Article	IF	CITATIONS
1008	JCS/JHRS 2019 guideline on nonâ€pharmacotherapy of cardiac arrhythmias. Journal of Arrhythmia, 2021, 37, 709-870.	0.5	91
1009	Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions. Heart Failure Reviews, 2022, 27, 1201-1210.	1.7	18
1010	Direct oral anticoagulants for electrical cardioversion. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2932.	0.4	0
1011	Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circulation: Arrhythmia and Electrophysiology, 2021, 14, HAE000000000000000078.	2.1	54
1012	Costâ€Utility of Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure: An Economic Evaluation. Journal of the American Heart Association, 2021, 10, e019599.	1.6	13
1013	Impact of Atrial Fibrillation on the Prognosis of Acute Decompensated Heart Failure With and Without Mitral Regurgitation. Circulation Reports, 2021, 3, 388-395.	0.4	1
1014	Rhythm control strategy in the transcatheter ablation era. Journal of Clinical Medicine of Kazakhstan, 2021, 18, 12-15.	0.1	0
1015	Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. European Heart Journal, 2022, 43, 1219-1230.	1.0	84
1016	Atrial Fibrillation Related Mortality: Another Curve to Bend. Journal of the American Heart Association, 2021, 10, e022555.	1.6	6
1017	2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology, 2021, 26, 4594.	0.4	89
1018	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. Europace, 2022, 24, 202-210.	0.7	9
1019	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
1020	Atrial Fibrillation Ablation in Heart Failure Patients. Journal of Clinical Medicine, 2021, 10, 3512.	1.0	1
1021	JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies. Circulation Journal, 2021, 85, 1590-1689.	0.7	45
1022	Review of the 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation—What Has Changed and How Does This Affect Daily Practice. Journal of Clinical Medicine, 2021, 10, 3922.	1.0	5
1023	LVSâ€HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a Worldâ€Wide Registry. Journal of the American Heart Association, 2021, 10, e017735.	1.6	4
1024	Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation, 2021, 144, 845-858.	1.6	111
1025	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. British Journal of Haematology, 2022, 196, 70-78.	1.2	14

#	Article	IF	CITATIONS
1026	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. Europace, 2022, 24, 552-564.	0.7	22
1027	Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF). Open Heart, 2021, 8, e001739.	0.9	1
1028	Impact of exercise capacity on the long-term incidence of atrial arrhythmias in heart failure. Scientific Reports, 2021, 11, 18705.	1.6	2
1029	Defining the benefit: Cardioversion of persistent atrial fibrillation. IJC Heart and Vasculature, 2021, 36, 100882.	0.6	0
1030	Prevention and Management of Perioperative Dysrhythmias. , 2022, , 191-206.		0
1032	Arrhythmia-Induced Cardiomyopathy. Indian Journal of Clinical Cardiology, 2021, 2, 90-96.	0.3	2
1033	Catheter Ablation Compared with Medical Therapy for Atrial Fibrillation with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. International Journal of Medical Sciences, 2021, 18, 1325-1331.	1.1	11
1034	Rhythm Control of Persistent Atrial Fibrillation in Systolic Heart Failure: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. International Journal of Heart Failure, 2021, 3, 179.	0.9	1
1035	Atrial Fibrillation. New England Journal of Medicine, 2021, 384, 353-361.	13.9	73
1036	Classification and choice of antiarrhythmic therapies. The Prescriber, 2020, 31, 11-17.	0.1	8
1037	Changing the Paradigm to Understand and Manage Atrial Fibrillation. , 2014, , 127-164.		2
1038	Arrhythmias in Dilated Cardiomyopathy: Diagnosis and Treatment. , 2019, , 149-171.		5
1039	Approach to Arrhythmia in Heart Failure. , 2016, , 243-267.		1
1041	Herztherapeutika. , 2014, , 681-699.		1
1042	Herztherapeutika. , 2016, , 485-497.		1
1043	NHC-Standaard Atriumfibrilleren. , 2011, , 313-339.		2
1044	Antiarrhythmic Drugs and Strategies. , 2009, , 235-292.		5
1046	Cardiovascular Disease in the Elderly. , 2012, , 1727-1756.		11

ARTICLE IF CITATIONS Rhythm and rate control of atrial fibrillation in the emergency department – A large community-based 1047 0.5 5 observational study. Canadian Journal of Emergency Medicine, 2018, 20, 834-840. Diabetes Mellitus and Metabolic Syndrome., 2009, , 465-496. 1048 Is rate more important than rhythm in treating atrial fibrillation? Yes. BMJ: British Medical Journal, 1050 2.4 5 2009, 339, b3173-b3173. Is rate more important than rhythm in treating atrial fibrillation? No. BMJ: British Medical Journal, 2.4 2009, 339, b3174-b3174. Management of atrial fibrillation. BMJ: British Medical Journal, 2009, 339, b5216-b5216. 1052 2.4 26 HeartQuake., 2020, 4, 1-28. Management of tachyarrhythmias in pregnancy – A review. Obstetric Medicine, 2020, 13, 159-173. 1054 0.5 5 Atrial Fibrillation Does Not Matter in Japanese Ventricular Assist Device Patients? ― Half-Way Up the Hill ―. Circulation Journal, 2019, 83, 1202-1203. The Association Between the Use of Antiarrhythmic Drugs in Non-Valvular Atrial Fibrillation and 1056 Patient Prognosis Using Data from the China Atrial Fibrillation (China-AF) Registry. Medical Science 0.5 3 Monitor, 2019, 25, 4856-4868. Management of atrial fibrillation. F1000prime Reports, 2014, 6, 22. Rhythm Versus Rate Control for Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. 1058 0.2 11 Biomedical and Pharmacology Journal, 2018, 11, 609-620. New-Onset Atrial Fibrillation Is a Predictor of Subsequent Hyperthyroidism: A Nationwide Cohort 1.1 24 Study. PLoS ONE, 2013, 8, e57893. Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International 1060 1.1 7 RealiseAF Survey. PLoS ONE, 2016, 11, e0147536. The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. PLoS ONE, 2017, 12, 1.1 e0186856. Turkish Society of Cardiology Consensus Paper on Management of Arrhythmia-Induced 1062 0.58 Cardiomyopathy. Anatolian Journal of Cardiology, 2019, 21, 98-106. Atrial Fibrillation Ablation in Patients with Heart Failure: One Size Does Not Fit All. Arrhythmia and 1063 Electrophysiology Review, 2018, 7, 84. Atrial Fibrillation and Stroke in Elderly Patients. Journal of Patient-centered Research and Reviews, 1064 0.6 5 2016, 3, 217-229. 2018 Korean Guidelines for Catheter Ablation of Atrial Fibrillation: Part I. International Journal of Arrhythmia, 2018, 19, 186-234.

# 1066	ARTICLE Current management of atrial fibrillation. Australian Prescriber, 2011, 34, 100-104.	IF 0.5	Citations 5
1067	Atrial Fibrillation. Deutsches Ärzteblatt International, 2012, 109, 1-7.	0.6	19
1068	Is catheter ablation for atrial fibrillation superior to pharmacotherapy?. Cor Et Vasa, 2010, 52, 9-16.	0.1	1
1069	Fibrilace sÃnÃ: Cor Et Vasa, 2011, 53, 27-52.	0.1	8
1070	Advances in the management of atrial fibrillation in congestive heart failure. F1000 Medicine Reports, 2009, 1, .	2.9	1
1071	Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure. International Journal of Heart Failure, 2019, 1, 4.	0.9	45
1072	2018 Korean Heart Rhythm Society Guidelines for Antiarrhythmic Drug Therapy in Non-valvular Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 140-152.	0.1	3
1073	The role of rotors in atrial fibrillation. Journal of Thoracic Disease, 2015, 7, 142-51.	0.6	27
1074	Management Of Atrial Fibrillation In Patients With Heart Failure. Journal of Atrial Fibrillation, 2014, 7, 1105.	0.5	1
1075	Atrial Fibrillation: The New Epidemic of the Ageing World. Journal of Atrial Fibrillation, 2009, 1, 154.	0.5	21
1076	California study of Ablation (CAABL):early utilization after index hospitalization for non-valvular atrial fibrillation. Journal of Atrial Fibrillation, 2017, 10, 1599.	0.5	2
1077	California Study of Ablation for Atrial Fibrillation:Re-hospitalization for Cardiac Events (CAABL-CE). Journal of Atrial Fibrillation, 2018, 11, 2036.	0.5	3
1078	Atrial Fibrillation in Heart Failure Patients with Preserved or Reduced Ejection Fraction. Prognostic significance of Rhythm control strategy with Catheter Ablation. Journal of Atrial Fibrillation, 2019, 11, 2128.	0.5	14
1079	Current Perspectives: Rheumatic Atrial Fibrillation. Journal of Atrial Fibrillation, 2010, 2, 222.	0.5	5
1080	Meta-Analysis of Catheter Ablation versus Medical Therapy in Patients with Atrial Fibrillation Without Heart Failure. Journal of Atrial Fibrillation, 2020, 12, 2266.	0.5	6
1081	Preventative Measures of Stroke in Patients With Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 4, 399.	0.5	2
1082	Atrial Fibrillation in Patients with Ischemic and Non-Ischemic Left Ventricular Dysfunction. Journal of Atrial Fibrillation, 2013, 5, 535.	0.5	4
1083	Atrial Fibrillation and Heart Failure: A Review of the Intersection of Two Cardiac Epidemics. Journal of Atrial Fibrillation, 2013, 6, 751.	0.5	23

#	Article		CITATIONS
1084	Present concepts in management of atrial fibrillation: From drug therapy to ablation. World Journal of Cardiology, 2009, 1, 11.		6
1085	Atrial fibrillation in heart failure: The sword of damocles revisited. World Journal of Cardiology, 2013, 5, 215.		21
1086	Atrial fibrillation practice patterns among cardiac electrophysiologists and cardiologists. Cardiology Journal, 2014, 21, 293-298.	0.5	4
1087	Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months. Cardiology Journal, 2014, 21, 397-404.	0.5	5
1088	Impact of successful restoration of sinus rhythm in patients with atrial fibrillation and acute heart failure: Results from the Korean Acute Heart Failure registry. Cardiology Journal, 2022, 29, 472-480.	0.5	3
1089	The clinical, electrocardiographic and echocardiographic characteristics and long-term outcome of patients with tachycardia-induced cardiomyopathy. Cardiovascular Journal of Africa, 2012, 23, 136-142.	0.2	8
1090	II Diretrizes Brasileiras de Fibrilação Atrial. Arquivos Brasileiros De Cardiologia, 2016, 106, .	0.3	24
1091	Prevalence of oral anticoagulation in atrial fibrillation. Clinics, 2014, 69, 615-620.	0.6	14
1092	Atrial fibrillation. Journal of Biomedical Research, 2014, 28, 1.	0.7	49
1093	ä,œ•´è,,^å┤ç"ç©¶ã®é€²æ©(循環噓å┤2008å¹´ã®é€²æ©). Journal of JCS Cardiologists, 2008, 16, 332-338.	0.1	0
1094	Which Therapy for Which Condition?. , 2009, , 388-458.		1
1095	Herztherapeutika. , 2009, , 581-596.		0
1096	Beyond AFFIRM, J-RHYTHM and AF-CHF study : ã,¨ãf"ãf‡ãf³ã,¹ãŒèªžã,‹ãfªã,ºãf管ç†ã®ç¾çжãë展望. Japanes	se (poo rnal	of@lectrocar
1097	å¿fä,å¨ç"ç©¶ã®é€²æ©(循環噓å¦2008å¹´ã®é€²æ©). Journal of JCS Cardiologists, 2009, 17, 98-103.	0.1	0
1098	Atrial Fibrillation and Managed Care: Current Approaches and Future Directions for Long-Term Therapy. Journal of Managed Care Pharmacy, 2009, 15, 1-39.	2.2	0
1099	Pathophysiology of Heart Failure. , 2010, , 1-27.		0
1100	Estudios electrofisiológicos, efectividad real de ablación en arritmias y sus complicaciones en Antofagasta como centro de derivación de la segunda región de Chile. Revista Chilena De CardiologÃa, 2009, 28, .	0.0	0
1101	Chronic heart failure - focused on women. Cor Et Vasa, 2009, 51, 805-812.	0.1	0

#	Article	IF	CITATIONS
1102	Staying Up To Date. , 2010, , 177-197.		0
1103	Herztherapeutika. , 2010, , 609-625.		0
1104	Acute Decompensated Cardiac Failure. , 2010, , 323-342.		0
1105	Atrial Fibrillation and Heart Failure Syndromes. , 2010, , 289-308.		0
1107	Atrial Fibrillation: Non Surgical Management. , 2010, , 133-143.		0
1108	Common Atrial and Ventricular Arrhythmias. , 2011, , 459-496.		Ο
1109	Pharmacologic Management of Atrial Fibrillation and Flutter. , 2011, , 165-193.		0
1110	2.åįfä¸ů¨ã«ä¼´ã†åįƒæ^;ç°å«ã®æ²»ç™,æ^¦ç•¥. Japanese Journal of Electrocardiology, 2011, 31, 346-355.	0.0	0
1111	Cardioversion and defibrillation. , 2011, , 393-400.		0
1113	å;fä,å¨ã,₿f™ãf³ãf^æŠʻå^¶ã®è¦³ç,1ã•ã,‰ãෑãŸå;fæ^;ç°å‹•ã,³ãf³ãf^ãfãf1⁄4ãf«ã®æ"義. Japanese Journal of E	lectoocard	i d ogy, 201
1114	Herztherapeutika. , 2011, , 627-644.		0
1115	Comparison of the Clinical Efficacy of Cardiac Resynchronization Therapy in Patients with Sinus Rhythm and Atrial Fibrillation. Japanese Journal of Electrocardiology, 2011, 31, 459-466.	0.0	Ο
1116	6.å¿fä¸å¨ã«ä¼´ã†ä¸œ•´è"^ã®ã,¢ãffãf—ã,¹ãf^ãfªãf¼ãfæ²»ç™,. Japanese Journal of Electrocardiology, 2011,	, 301. 0387-3	93.
1118	å;fä,å¨â,'有ãı™ã,‹å;fæ^;ç°å‹•ã®è−¬ç‰©çš,,æ²»ç™,æ³•ã®æ^¦ç•¥ãëãã®å®Ÿéš>. Japanese Journal of Electroc	a cdio logy,	2011, 31, 1
1120	Strategies for the Management of Postoperative Atrial Fibrillation. Orthopedics, 2011, 34, 377-382.	0.5	2
1122	Antiarrhythmic drugs for maintaining of sinus rhythm. Interventional Medicine & Applied Science, 2011, 3, 116-119.	0.2	Ο
1123	Implications of Atrial Fibrillation in Heart Failure Management. Contemporary Cardiology, 2012, , 237-252.	0.0	0

1124	The attractiveness of beta-blockers for the treatment of atrial fibrillation : rate & rhythm control. Japanese Journal of Electrocardiology, 2012, 32, 199-201.	0.0	0
------	--	-----	---

#	Article	IF	CITATIONS
1127	Herztherapeutika. , 2012, , 633-651.		0
1129	Management Options in Atrial Fibrillation – The Role of Vernakalant. The European Journal of Cardiovascular Medicine, 2012, , .	1.0	0
1137	Management of arrhythmias in heart failure. What a practicing physician should know in the current times. Cardiology Journal, 2012, 19, 567-577.	0.5	1
1139	Atrial fibrillation ablation in patients with heart failure review. World Journal of Cardiovascular Diseases, 2013, 03, 49-57.	0.0	0
1140	Consideration on Drug Therapy of Atrial Fibrillation from Standpoint of Heart Failure Treatment. Japanese Journal of Electrocardiology, 2013, 33, 129-134.	0.0	0
1141	Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves. , 2013, , 786-799.		0
1144	Application of New Oral Anticoagulants: Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation. Korean Journal of Medicine, 2014, 87, 26.	0.1	0
1145	Atrial Fibrillation and Heart Failure in the Aging Population. , 2014, , 65-84.		0
1146	Vorhofflimmern. , 2014, , 1-12.		0
1147	Antiarrhythmic Drug Therapy for Atrial Fibrillation in Patients with Left Ventricular Dysfunction. Japanese Journal of Electrocardiology, 2014, 33, 449-457.	0.0	0
1148	Acute Decompensated Cardiac Failure. , 2015, , 445-470.		0
1150	Herztherapeutika. , 2015, , 687-707.		0
1151	Arrhythmias in Heart Failure. , 2015, , 151-166.		0
1152	Impaired quality of life in patients with intermittent atrial fibrillation. Anatolian Journal of Cardiology, 2015, 16, 250-5.	0.5	5
1154	é‡è¦è«—æ—‡ã,'解説ã™ã,‹. Japanese Journal of Electrocardiology, 2016, 36, 137-137.	0.0	0
1155	Catheter ablation for atrial fibrillation-therapeutic dilemmas. Srce I Krvni Sudovi, 2016, 35, 23-27.	0.1	0
1156	Herztherapeutika. , 2017, , 491-503.		0
1157	Atrial Arrhythmias and Heart Failure. , 2017, , 327-338.		0

#	Article	IF	CITATIONS
1158	Implications of Atrial Fibrillation in Heart Failure Management. Contemporary Cardiology, 2017, , 269-284.	0.0	0
1159	Epidemiologic Transition and Heart Failure in Black African Adults. World Journal of Cardiovascular Diseases, 2017, 07, 358-366.	0.0	0
1160	Arrhythmias in Cardiomyopathy. , 2017, , 285-321.		0
1161	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Therapeutic Options. Cardiologia Croatica, 2017, 12, 254-263.	0.0	1
1162	OBSOLETE: Clinical Trials for Atrial Fibrillation - What do we know?. , 2018, , .		0
1163	Catheter Ablation for Atrial Fibrillation in Patients with Heart FailureMauricio Scanavacca and Edimar Alcides Bocchi. Arquivos Brasileiros De Cardiologia, 2018, 110, 300-302.	0.3	1
1164	Herztherapeutika. , 2018, , 539-552.		0
1165	Prim¤pr¤ention und Sekund¤pr¤ention des Hirninfarkts. Springer Reference Medizin, 2018, , 1-31.	0.0	0
1166	OBSOLETE: Cardiac Arrhythmias in Heart Failure. , 2018, , .		0
1167	Catheter ablation of atrial fibrillation in heart failure patients. Intervencni A Akutni Kardiologie, 2018, 17, 82-84.	0.0	Ο
1169	2018 Korean Heart Rhythm Society Guidelines for Detection and Management of Risk Factors and Concomitant Cardiovascular Diseases in Korean Patients with Atrial Fibrillation. Korean Journal of Medicine, 2018, 93, 324-335.	0.1	2
1171	Arrhythmias and conductance disturbances and heart failure. Vnitrni Lekarstvi, 2018, 64, 874-877.	0.1	1
1172	Copyright and licensing of E-journals:. Japanese Journal of Electrocardiology, 2018, 38, 221-227.	0.0	0
1173	Herztherapeutika. , 2019, , 701-717.		0
1174	Current Management and Treatment. , 2019, , 199-215.		1
1175	Cardiovigilance in Atrial Fibrillation – Primordial to Quinary Prevention Intervention. European Journal of Arrhythmia & Electrophysiology, 2019, 5, 77.	0.2	Ο
1176	Atrial Fibrillation Ablation – Benefits Beyond Symptom Reduction with a Focus on Patients with Heart Failure with Reduced Ejection Fraction. European Journal of Arrhythmia & Electrophysiology, 2019, 5, 30.	0.2	0
1177	Addressing the Challenge of Atrial Fibrillation Management: How to Differentiate the Approach Depending on Left Ventricular Ejection Fraction. Cardiology Research, 2019, 10, 253-254.	0.5	0

	CITATION	N REPORT	
#	Article	IF	CITATIONS
1178	Primäpräention und Sekundäpräention des Hirninfarkts. Springer Reference Medizin, 2019, , 1-31.	0.0	0
1179	Atrial Fibrillation: From a Lot of Information to a Simple Principle. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 193-195.	0.0	0
1181	VI. Rate Control Therapy: Therapeutic Target and Use Drugs. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 234-241.	0.0	0
1183	Arrhythmia-Induced Cardiomyopathies. Contemporary Cardiology, 2020, , 547-567.	0.0	0
1184	Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure. Cardiac Failure Review, 2020, 6, e04.	1.2	0
1185	The Care of Patients With Atrial Fibrillation and Heart Failure. Critical Pathways in Cardiology, 2021, 20, 93-99.	0.2	1
1186	Impact of the Temporal Relationship Between Atrial Fibrillation and Heart Failure on Prognosis After Ablation. Circulation Journal, 2020, 84, 1467-1474.	0.7	5
1187	Catheter Ablation vs. Medical Treatment in Patients With Atrial Fibrillation. Cureus, 2020, 12, e9700.	0.2	0
1188	Novel Rhythm Control for Atrial Fibrillation. Journal of the Nihon University Medical Association, 2020, 79, 221-224.	0.0	0
1189	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAI DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020 Eurasian Heart Journal, 2020, , 6-76.		6
1190	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. BMJ, The, 2021, 375, e066450.	3.0	6
1191	Impact of Rhythm vs. Rate Control in Atrial Fibrillation on the Long-Term Outcome of Patients Undergoing Transcatheter Edge-to-Edge Mitral Valve Repair. Journal of Clinical Medicine, 2021, 10, 5044.	1.0	3
1192	Atrial Fibrillation and Heart Failure. AACN Advanced Critical Care, 2020, 31, 431-434.	0.6	1
1193	Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry. Chinese Medical Journal, 2021, 134, 309-317.	0.9	0
1195	Precise Drug Sequential Therapy Can Improve the Cardioversion Rate of Atrial Fibrillation with Valvular Disease after Radiofrequency Ablation. Methods in Molecular Biology, 2020, 2204, 145-159.	0.4	0
1197	Cardiac Dysrhythmias. , 2020, , 141-163.		0
1198	Pharmacologic Management of Atrial Fibrillation and Flutter. Contemporary Cardiology, 2020, , 359-407.	0.0	0
1199	Herztherapeutika. , 2020, , 555-570.		0

			2
#	ARTICLE	IF	CITATIONS
1200	Primäpräention und Sekundäpräention des Hirninfarkts. Springer Reference Medizin, 2020, , 883-913.	0.0	0
1202	Advances in the management of atrial fibrillation with a special focus on non-pharmacological approaches to prevent thromboembolism: a review of current recommendations. Journal of Investigative Medicine, 2020, 68, 1317-1333.	0.7	0
1203	Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature. Cardiovascular Innovations and Applications, 2020, 5, .	0.1	2
1204	Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clinic Proceedings, 2009, 84, 234-42.	1.4	19
1205	Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena?. Indian Pacing and Electrophysiology Journal, 2009, 9, 334-41.	0.3	3
1207	Rate versus rhythm in atrial fibrillation: and how slow do you go?. Canadian Family Physician, 2011, 57, 1411.	0.1	0
1208	Atrial fibrillation (chronic). Clinical Evidence, 2011, 2011, .	0.2	1
1209	Drug therapy in atrial fibrillation management: where do we stand in 2010?. The Journal of Tehran Heart Center, 2010, 5, 172-8.	0.3	0
1210	Rate versus rhythm control in atrial fibrillation. Canadian Family Physician, 2013, 59, 161-8.	0.1	5
1211	Atrial fibrillation in patients with heart failure: Role of catheter ablation therapies. Experimental and Clinical Cardiology, 2012, 17, 237-42.	1.3	2
1212	Correlation between CHADS2 score and anticoagulant use in atrial fibrillation: Results of a mini-survey. Experimental and Clinical Cardiology, 2013, 18, 101-3.	1.3	1
1213	The reversal of cardiology practices: interventions that were tried in vain. Cardiovascular Diagnosis and Therapy, 2013, 3, 228-35.	0.7	6
1214	Use Of Rate And Rhythm Control Drugs In Patients Younger Than 65 Years With Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 7, 1062.	0.5	3
1215	A practical approach to the management of patients with atrial fibrillation. Heart Asia, 2010, 2, 95-103.	1.1	1
1216	Atrial Fibrillation and Heart Failure. Journal of Atrial Fibrillation, 2008, 1, 101.	0.5	2
1217	Ablation of Atrial Fibrillation in Combination with Left Atrial Appendage Occlusion in A Single Procedure. Rationale and Technique. Journal of Atrial Fibrillation, 2016, 8, 1346.	0.5	2
1218	Emergency Department Readmission in Elderly Patients After Acute Rhythm or Rate Control Treatment for Atrial Fibrillation. Journal of Atrial Fibrillation, 2016, 9, 1387.	0.5	0
1219	Who Needs Pharmacologic Therapy?. Journal of Atrial Fibrillation, 2014, 7, 1084.	0.5	0

		CITATION RE	PORT	
#	Article		IF	Citations
1220	Who Needs Catheter Ablation And Which Approach?. Journal of Atrial Fibrillation, 2015	5, 8, 1335.	0.5	1
1221	Atrial Fibrillation In Heart Failure: New Directions In Diagnosis, Risk Assessment And Ris Journal of Atrial Fibrillation, 2014, 6, 1036.	sk Reduction.	0.5	0
1222	Effect Of Catheter Ablation On Quality Of Life In Atrial Fibrillation. Journal of Atrial Fibr 2014, 6, 1063.	illation,	0.5	2
1223	Necessity of Repeat Ablations to Eliminate Atrial Fibrillation. Journal of Atrial Fibrillatior	n, 2012, 4, 469.	0.5	0
1224	Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Options. Journal of Atrial Fibrillation, 2012, 4, 477.	n Therapeutic	0.5	0
1225	Cardiac Resynchronization Therapy and Atrial Fibrillation. Journal of Atrial Fibrillation, 2	011, 4, 334.	0.5	0
1226	Rate Control in Atrial Fibrillation: Methods for Assessment, Targets for Ventricular Rate and Clinical Relevance for Device Therapy. Journal of Atrial Fibrillation, 2013, 6, 791.	during AF,	0.5	1
1227	Thinking outside the Box: Rotor Modulation in the Treatment of Atrial Fibrillation. Jourr Fibrillation, 2013, 6, 811.	nal of Atrial	0.5	0
1228	Anti-Arrhythmic Agents in the Treatment of Atrial Fibrillation. Journal of Atrial Fibrillatio 864.	n, 2013, 6,	0.5	1
1229	Atrial Fibrillation Associated with Heart Failure, Stroke and Mortality. Journal of Atrial F 2012, 5, 467.	brillation,	0.5	10
1230	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Managen Outcome. Journal of Atrial Fibrillation, 2013, 5, 748.	ient and	0.5	0
1231	Role of Bi-Atrial Pacing In Slowing The Progression of Paroxysmal Atrial Fibrillation To P Atrial Fibrillation. Journal of Atrial Fibrillation, 2013, 6, 856.	ermanent	0.5	0
1232	Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The F Node Ablation. Journal of Atrial Fibrillation, 2012, 4, 438.	tole of AV	0.5	0
1233	Atrial Fibrillation - A Common Ground for Neurology and Cardiology. Journal of Atrial Fi 2013, 6, 550.	brillation,	0.5	0
1234	Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure. Jo Atrial Fibrillation, 2013, 6, 740.	urnal of	0.5	3
1235	Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Tria Emergency, 2017, 5, e29.	l.	0.6	1
1236	Atrial fibrillation: a leading cause of heart failure-related hospitalizations; a dual epidem Journal of Cardiovascular Disease, 2019, 9, 109-115.	ıic. American	0.5	7
1237	Rhythm Control in Heart Failure Patients with Atrial Fibrillation. Arrhythmia and Electro Review, 2020, 9, 161-166.	physiology	1.3	0

#	Article	IF	CITATIONS
1238	Catheter ablation for atrial fibrillation in heart failure: untying the Gordian knot. Journal of Geriatric Cardiology, 2021, 18, 297-306.	0.2	2
1239	Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. Journal of Geriatric Cardiology, 2021, 18, 362-375.	0.2	1
1240	Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. Journal of Geriatric Cardiology, 2021, 18, 376-397.	0.2	1
1241	Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). Experimental and Therapeutic Medicine, 2021, 22, 1463.	0.8	1
1242	Surgical ablation in rheumatic heart disease—Uncharted territory. Journal of Cardiac Surgery, 2021, , .	0.3	0
1243	Bayesian Network Metaâ€Analysis Comparing Cryoablation, Radiofrequency Ablation, and Antiâ€arrhythmic Drugs as Initial Therapies for Atrial Fibrillation Journal of Cardiovascular Electrophysiology, 2021, , .	0.8	3
1244	Herztherapeutika. , 2021, , 461-476.		0
1245	Association of rhythm control with incident dementia among patients with atrial fibrillation: a nationwide population-based cohort study. Age and Ageing, 2022, 51, .	0.7	18
1246	Rhythm Control in Heart Failure Patients with Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2020, 9, 161-166.	1.3	5
1247	Advances in Atrial Fibrillation Ablation. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 2400-2406.	0.0	1
1249	The 2020 ESC atrial fibrillation guidelines for atrial fibrillation catheter ablation, CABANA, and EAST. Europace, 2022, 24, ii3-ii7.	0.7	6
1251	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
1252	Impact of Atrial Tachyarrhythmia Recurrence on the Development of Longâ€Term Adverse Clinical Events Following Catheter Ablation in Patients With Atrial Fibrillation With Systolic Impairment: A Singleâ€Center Observational Study. Journal of the American Heart Association, 2022, 11, e023640.	1.6	3
1253	Electrical management of heart failure: from pathophysiology to treatment. European Heart Journal, 2022, 43, 1917-1927.	1.0	16
1254	Very early versus early referral for ablation among young patients for newly diagnosed paroxysmal atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2022, , .	0.5	2
1255	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning. Heart Failure Reviews, 2022, 27, 1761-1777.	1.7	3
1257	MEDEX South Carolina: a progress report. The Journal of the South Carolina Medical Association, 1975, 71, 337-8.	0.0	0
1258	Machine Learning Using a Single-Lead ECG to Identify Patients With Atrial Fibrillation-Induced Heart Failure. Frontiers in Cardiovascular Medicine, 2022, 9, 812719.	1.1	2

ARTICLE IF CITATIONS Catheter ablation of atrial fibrillation: Current status and near future. Journal of Cardiology, 2022, 1259 0.8 3 Newly developed atrial fibrillation in the perioperative setting: what to do next?. Minerva Anestesiologica, 2022, , . Left atrial appendage exclusion in patients with atrial fibrillation: Should it become standard of care?. 1261 0.3 0 Journal of Cardiac Surgery, 2022, 37, 1139-1141. Temporal trends and predictors of surgical ablation for atrial fibrillation across a multistate 1262 healthcare system. Heart Rhythm O2, 2022, 3, 32-39. Catheter ablation improves outcomes and quality of life in Japanese patients with early-stage atrial 1265 0.3 2 fibrillation: A retrospective cohort study. Heart Rhythm, 2022, 19, 1076-1083. <scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Journal of Arrhythmia, 2022, 38, 833-973. 1266 Management of Atrial Tachyarrhythmias in Heart Failureâ€"an Interventionalist's Point of View. 1267 1.3 0 Current Heart Failure Reports, 2022, , 1. Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and 1.0 1268 Rhythm Control Strategies. American Journal of Cardiovascular Drugs, 2022, , 1. Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the 1269 0.4 2 left ventricular ejection fraction spectrum. Hellenic Journal of Cardiology, 2022, 66, 32-40. JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. Circulation Journal, 2022, 86, 1270 49 1790-1924. Prediction of Successful Pharmacological Cardioversion in Acute Symptomatic Atrial Fibrillation: The Successful Intravenous Cardioversion for Atrial Fibrillation (SIC-AF) Score. Journal of Personalized 1271 1.1 0 Medicine, 2022, 12, 544. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure 1.6 54 and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation, 2022, 145, 1693-1704. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in 1273 0.7 11 the emergency department. American Journal of Emergency Medicine, 2022, 58, 39-42. Treatment strategies for patients with atrial fibrillation and chronic heart failure. Terapevticheskii Arkhiv, 2021, 93, 1545-1550. 1274 0.2 Interventional heart failure therapy: A new concept fighting against heart failure. Journal of 1275 0.8 18 Cardiology, 2022, 80, 101-109. The Relationship Between Atrial Fibrillation, Mitral Regurgitation, and Heart Failure Subtype: The ARIC 1276 Study. Journal of Cardiac Failure, 2022, 28, 883-892. Cryoballoon Ablation for the Treatment of Atrial Fibrillation in Patients With Concomitant Heart 1277 Failure and Either Reduced or Preserved Left Ventricular Ejection Fraction: Results From the Cryo AF 1.6 8 Global Registry. Journal of the American Heart Association, 2021, 10, e021323. Meta-Analysis of Catheter Ablation versus Medical Therapy for Heart Failure Complicated with Atrial 1278 Fibrillation. Cardiology Research and Practice, 2021, 2021, 1-9.

~		~	
(11	ГАТ	DEI	PORT
	IAL	NL	PORT

#	Article	IF	CITATIONS
1279	Comparative Effectiveness of Early Rhythm Control Versus Rate Control for Cardiovascular Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2021, 10, e023055.	1.6	21
1280	Rhythm control in asymptomatic â€~early' atrial fibrillation: birth of a new paradigm?. European Heart Journal, 2022, 43, 1231-1233.	1.0	1
1281	Atrial fibrillation and heart failure: A contemporary review of current management approaches. Heart Rhythm O2, 2021, 2, 762-770.	0.6	10
1282	Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival. PLoS ONE, 2021, 16, e0260350.	1.1	8
1283	Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace, 2023, 25, 6-27.	0.7	65
1284	Evaluation and Interventional Management of Cardiac Dysrhythmias. Surgical Clinics of North America, 2022, 102, 365-391.	0.5	0
1285	Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society. Journal of Interventional Cardiac Electrophysiology, 2022, 65, 287-326.	0.6	20
1286	GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
1287	Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation. Clinical Research in Cardiology, 2022, , 1.	1.5	1
1316	Atrial Fibrillation and Heart Failure. Journal of Clinical Medicine, 2022, 11, 2510.	1.0	8
1317	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1932-1948.	1.2	63
1318	Which therapy for which condition?. , 2013, , 463-541.		1
1319	Antiarrhythmic drugs and strategies. , 2013, , 272-331.		4
1320	ATRIAL FIBRILLATION: THE STAGES OF TREATMENT AND DIAGNOSTIC MEASURES (literature review). Problemy Zdorovʹâ I ðkologii, 2013, , 14-21.	0.0	0
1321	Saikokaryukotsuboreito Could be Effective Even if Shakanzoto is Ineffective for Paroxysmal Atrial Fibrillation with Strong Palpitation after Cardiac Surgery. Kampo Medicine, 2021, 72, 27-33.	0.1	0
1322	Efficacy of statins combined with amiodarone in the treatment of atrial fibrillation: A meta-analysis. European Journal of Inflammation, 2022, 20, 1721727X2210944.	0.2	0
1323	Pharmacologic Rate versus Rhythm Control for Atrial Fibrillation in Heart Failure Patients. Medicina (Lithuania), 2022, 58, 743.	0.8	1
1324	Generalizability of the EASTâ€AFNET 4 Trial: Assessing Outcomes of Early Rhythmâ€Control Therapy in Patients With Atrial Fibrillation. Journal of the American Heart Association, 2022, 11, .	1.6	14

			_
#	Article	IF	CITATIONS
1325	Gene therapy to terminate tachyarrhythmias. Expert Review of Cardiovascular Therapy, 2022, 20, 431-442.	0.6	0
1327	Predicting Late Recurrence of Atrial Fibrillation After Radiofrequency Ablation in Patients With Atrial Fibrillation: Comparison of C2HEST and HATCH Scores. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
1328	How to Optimize Cardioversion of Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 3372.	1.0	1
1329	Optimal Rhythm Control Strategy in Patients With Atrial Fibrillation. Korean Circulation Journal, 2022, 52, 496.	0.7	12
1330	Variation in heart rate range by 24â€h Holter monitoring predicts heart failure in patients with atrial fibrillation. ESC Heart Failure, 2022, 9, 3092-3100.	1.4	2
1331	Improved survival in patients with atrial fibrillation and heart failure undergoing catheter ablation compared to medical treatment: A systematic review and metaâ€analysis of randomized controlled trials. Journal of Cardiovascular Electrophysiology, 2022, 33, 2356-2366.	0.8	7
1332	An Integrative Comparative Study Between Digoxin and Amiodarone as an Emergency Treatment for Patients With Atrial Fibrillation With Evidence of Heart Failure: A Systematic Review and Meta-Analysis. Cureus, 2022, , .	0.2	1
1333	The physics of heart rhythm disorders. Physics Reports, 2022, 978, 1-45.	10.3	14
1334	Is Maintenance of Sinus Rhythm of Value in Patients with Atrial Fibrillation and Heart Failure?. Current Cardiology Reports, 2022, 24, 1227-1231.	1.3	1
1335	Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2022, 146, 339-357.	1.6	21
1336	Atrial Fibrillation in Heart Failure: Rate or Rhythm Control Strategy. , 0, , .		0
1338	Sex Difference in Effectiveness of Early Rhythm- over Rate-Control in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 4991.	1.0	3
1339	Comparison of catheter ablation and medical therapy for atrial fibrillation in heart failure patients: A meta-analysis of randomized controlled trials. Heart and Lung: Journal of Acute and Critical Care, 2023, 57, 69-74.	0.8	15
1340	Rapid Atrial Fibrillation in the Emergency Department. Heart International, 2022, 16, 12.	0.4	2
1342	Treatment of Arrhythmias During Pregnancy. Clinical Obstetrics and Gynecology, 0, Publish Ahead of Print, .	0.6	0
1343	Effect of concomitant surgical atrial fibrillation ablation in patients with reduced left ventricle ejection fraction: A propensityâ€score matching analysis. Journal of Cardiac Surgery, 2022, 37, 3598-3606.	0.3	1
1344	Clinical outcomes and structural remodelling after ablation of atrial fibrillation in heart failure with mildly reduced or midâ€range ejection fraction. ESC Heart Failure, 0, , .	1.4	3
1345	The Aged Heart. Emergency Medicine Clinics of North America, 2022, 40, 637-649.	0.5	3

#	Article	IF	CITATIONS
1346	Burden of atrial fibrillation among adults with heart failure in sub-Saharan Africa: a systematic review and meta-analysis. BMJ Open, 2022, 12, e061618.	0.8	1
1347	Recent Advances in Catheter Ablation for Atrial Fibrillation and Non-pharmacological Stroke Prevention. , 0, , .		0
1348	Target heart rate in heart failure with reduced ejection fraction and atrial fibrillation: Goldilocks zone. American Heart Journal Plus, 2022, 23, 100218.	0.3	1
1349	Atrial assistance device, a new alternative to lifelong anticoagulation?. Swiss Medical Weekly, 0, , .	0.8	2
1350	An aggressive solution for patients with heart failure and atrial fibrillation: nodal ablation and cardiac resynchronization therapy. European Heart Journal Supplements, 2022, 24, 122-124.	0.0	0
1351	Mobile health-technology integrated care in atrial fibrillation patients with heart failure: A report from the mAFA-II randomized clinical trial. European Journal of Internal Medicine, 2023, 107, 46-51.	1.0	2
1352	Should Catheter Ablation for Atrial Fibrillation be a Priority in Patients with Heart Failure with Reduced Ejection Fraction?. European Journal of Arrhythmia & Electrophysiology, 2022, 8, 20.	0.2	0
1353	Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurology, The, 2023, 22, 45-54.	4.9	15
1354	Le patient atteint de maladies cardiovasculaires. , 2022, , 99-122.		0
1355	Heart failure in patients with atrial fibrillation: Insights from Polish part of the EORPâ€AF general longâ€ŧerm registry. ESC Heart Failure, 2023, 10, 637-649.	1.4	3
1356	Atrial Fibrillation and CongestiveÂHeartÂFailure. JACC: Clinical Electrophysiology, 2022, 8, 1367-1368.	1.3	0
1357	Effect of Catheter Ablation for Atrial Fibrillation in Heart Failure With Mid-Range or Preserved Ejection Fraction ― Pooled Analysis of the AF Frontier Ablation Registry and Hokuriku-Plus AF Registry ―. Circulation Journal, 2023, 87, 939-946.	0.7	3
1358	The impact of catheter ablation in patient's heart failure and atrial fibrillation: a meta-analysis of randomized clinical trials. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 1487-1497.	0.6	1
1359	Coherence and correspondence in medicine. Judgment and Decision Making, 2009, 4, 134-140.	0.8	11
1360	Herzerkrankungen. , 2022, , 205-220.		0
1361	Catheter Ablation for Atrial Fibrillation Could Be a Promising Therapeutic Option in Patients With Heart Failure With Mid-Range or Preserved Ejection Fraction. Circulation Journal, 2023, , .	0.7	0
1362	A comprehensive meta-analysis comparing radiofrequency ablation versus pharmacological therapy for the treatment of atrial fibrillation in patients with heart failure. International Journal of Cardiology, 2023, 377, 66-72.	0.8	3
1363	Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease. Frontiers in Physiology, 0, 14, .	1.3	9

#	Article	IF	CITATIONS
1364	Early rhythm control vs. rate control in atrial fibrillation: A systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 0, 10, .	1.1	2
1365	Low ambient temperature increases the risk and burden of atrial fibrillation episodes: A nationwide case-crossover study in 322 Chinese cities. Science of the Total Environment, 2023, 880, 163351.	3.9	5
1366	Atrial fibrillation ablation as first-line therapy for patients with heart failure with reduced ejection fraction (HFrEF): evaluating the impact on patient survival. Expert Review of Cardiovascular Therapy, 2023, 21, 111-121.	0.6	2
1367	This is Your Brain, and This is Your Brain on Atrial Fibrillation: The Roles of Cardiac Malperfusion Events and Vascular Dysfunction in Cognitive Impairment. Arrhythmia and Electrophysiology Review, 0, 12, .	1.3	5
1368	ll. Details: Therapeutic Agents for Chronic Heart Failure; 5. Position of Digitalis as a Therapeutic Agent for Heart Failure, and Management of Heart Failure Patients with Atrial Fibrillation. The Journal of the Japanese Society of Internal Medicine, 2022, 111, 248-254.	0.0	0
1369	TaquicardiomiopatÃa: una causa reversible y poco reconocida de falla cardÃaca. latreia, 2013, 27, .	0.1	0
1370	Choice of sinus rhythm control strategy in patients with atrial fibrillation: why, when and how? A review. Journal of Arrhythmology, 2023, 30, 52-60.	0.1	0
1371	Heart failure with reduced ejection fraction and atrial fibrillation: a Subâ€Saharan African perspective. ESC Heart Failure, 2023, 10, 1580-1596.	1.4	3
1372	Benefits of early rhythm control of atrial fibrillation. Trends in Cardiovascular Medicine, 2023, , .	2.3	5
1373	Approach to atrial fibrillation. Canadian Family Physician, 2023, 69, 245-256.	0.1	1
1374	2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2023, 81, 1835-1878.	1.2	74
1411	Antiarrhythmic Treatment in Heart Failure. Current Heart Failure Reports, 2024, 21, 22-32.	1.3	0
1412	Fibrillation atriale et autres tachycardies. , 2023, , 251-259.		0
1417	Herzerkrankungen. , 2023, , 227-242.		0